Document:

EX-10.12

 Exhibit 10.12 
 EXECUTION VERSION 
 LOAN AND SECURITY AGREEMENT 

THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 20, 2011 and is entered into by and between REVANCE THERAPEUTICS,
INC., a Delaware corporation (hereinafter referred to as the “Borrower”) and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (“Lender”). 
 RECITALS 
 A. Borrower has requested Lender to make available to Borrower a
loan in an aggregate principal amount of up to Twenty Two Million Dollars ($22,000,000) (the “Term Loan”); and 
 B.
Lender is willing to make the Term Loan on the terms and conditions set forth in this Agreement. 
 AGREEMENT 

NOW, THEREFORE, Borrower and Lender agree as follows: 
 SECTION 1. DEFINITIONS AND RULES OF CONSTRUCTION 

1.1 Unless otherwise defined herein, the following capitalized terms shall have the following meanings: 

“Account Control Agreement(s)” means any agreement entered into by and among Lender, Borrower and a third party Bank or other
institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment Property and which grants Lender a perfected first priority security interest in the subject account or accounts.

 “ACH Authorization” means the ACH Debit Authorization Agreement in substantially the form of Exhibit H.

 “Advance” means the Term Loan Advance. 
 “Advance Date” means the funding date of the Term Loan Advance. 

“Advance Request” means a request for an Advance submitted by Borrower to Lender in substantially the form of Exhibit A.

 “Agreement” means this Loan and Security Agreement, as amended from time to time. 

“Assignee” has the meaning given to it in Section 11.13. 

“Borrower Products” means all products, software, service offerings, technical data or technology currently being designed,
manufactured or sold by Borrower or which Borrower intends to sell, license, or distribute in the future including any products or service offerings under development, collectively, together with all products, software, service offerings, technical
data or technology that have been sold, licensed or distributed by Borrower since its incorporation. 
 “Cash” means
all cash and liquid funds. 

 “Change in Control” means any reorganization, recapitalization, consolidation or
merger (or similar transaction or series of related transactions) of Borrower or any Subsidiary, sale or exchange of outstanding shares (or similar transaction or series of related transactions) of Borrower or any Subsidiary in which the holders of
Borrower or Subsidiary’s outstanding shares immediately before consummation of such transaction or series of related transactions do not, immediately after consummation of such transaction or series of related transactions, retain shares
representing more than fifty percent (50%) of the voting power of the surviving entity of such transaction or series of related transactions (or the parent of such surviving entity if such surviving entity is wholly owned by such parent), in
each case without regard to whether Borrower or Subsidiary is the surviving entity; provided that none of the following shall constitute a Change in Control: (i) any consolidation or merger effected exclusively to change the domicile of the
Company, (ii) the sale and issuance by Borrower of its equity securities to venture capital investors in a bona fide equity financing, or (iii) an Initial Public Offering. 

“Claims” has the meaning given to it in Section 11.10. 

“Closing Date” means the date of this Agreement. 
 “Collateral” means the property described in Section 3. 

“Commitment Fee” means $40,000, which fee is due to Lender on or prior to the Closing Date, and shall be deemed fully earned
on such date regardless of the early termination of this Agreement. 
 “Confidential Information” has the meaning
given to it in Section 11.12. 
 “Contingent Obligation” means, as applied to any Person, any direct or indirect
liability, contingent or otherwise, of that Person with respect to (i) any indebtedness, lease, dividend, letter of credit or other obligation of another, including any such obligation directly or indirectly guaranteed, endorsed, co-made or
discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit, corporate credit cards or merchant services issued
for the account of that Person; and (iii) all obligations arising under any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or other agreement or arrangement designated to
protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; provided, however, that the term “Contingent Obligation” shall not include endorsements for collection or deposit in the ordinary course
of business. The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent Obligation is made or, if not stated or determinable, the
maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the obligations under the guarantee or other support
arrangement. 
 “Copyright License” means any written agreement granting any right to use any Copyright or Copyright
registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest. 

“Copyrights” means all copyrights, whether registered or unregistered, held pursuant to the laws of the United States,
any State thereof, or of any other country. 
 “Deposit Accounts” means any “deposit accounts,” as such
term is defined in the UCC, and includes any checking account, savings account, or certificate of deposit. 
 “ERISA”
is the Employee Retirement Income Security Act of 1974, and its regulations. 

  
 2 

 “Event of Default” has the meaning given to it in Section 9. 

“Facility Charge” means $150,000. 
 “Financial Statements” has the meaning given to it in Section 7.1. 

“GAAP” means generally accepted accounting principles in the United States of America, as in effect from time to time.

 “Indebtedness” means indebtedness of any kind, including (a) all indebtedness for borrowed money or the
deferred purchase price of property or services (excluding trade credit entered into in the ordinary course of business due within sixty (60) days), including reimbursement and other obligations with respect to surety bonds and letters of
credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations, and (d) all Contingent Obligations. 

“Initial Public Offering” means the initial firm commitment underwritten offering of Borrower’s common stock pursuant to
a registration statement under the Securities Act of 1933 filed with and declared effective by the Securities and Exchange Commission. 
 “Insolvency Proceeding” is any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit of
creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief. 
 “Intellectual Property” means all of Borrower’s Copyrights, Trademarks, Patents, Licenses, trade secrets and inventions, mask works; Borrower’s applications therefor and reissues,
extensions, or renewals thereof; and Borrower’s goodwill associated with any of the foregoing, together with Borrower’s rights to sue for past, present and future infringement of Intellectual Property and the goodwill associated therewith.

 “Investment” means any beneficial ownership (including stock, partnership or limited liability company interests)
of or in any Person, or any loan, advance or capital contribution to any Person. 
 “Joinder Agreements” means for
each Subsidiary, a completed and executed Joinder Agreement in substantially the form attached hereto as Exhibit G. 

“Lender” has the meaning given to it in the preamble to this Agreement. 

“Lender Expenses” are all audit fees and expenses, costs, and expenses (including reasonable attorneys’ fees and
expenses) for preparing, negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings) or otherwise incurred with respect to Borrower.

 “License” means any Copyright License, Patent License, Trademark License or other license of rights or interests.

 “Lien” means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest,
encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, and any lease in the nature of a security
interest. 

  
 3 

 “Loan” means the Advance made under this Agreement. 

“Loan Documents” means this Agreement, the Note, the ACH Authorization, the Account Control Agreements, the Joinder
Agreements, all UCC Financing Statements, the Warrant, the Subordination Agreement, and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby, as the same may from time to time be amended,
modified, supplemented or restated. 
 “Material Adverse Effect” means a material adverse effect upon: (i) the
business, operations, properties, assets or condition (financial or otherwise) of Borrower; or (ii) the ability of Borrower to perform the Secured Obligations in accordance with the terms of the Loan Documents, or the ability of Lender to
enforce any of its rights or remedies with respect to the Secured Obligations; or (iii) the Collateral or Lender’s Liens on the Collateral or the priority of such Liens. 

“Maximum Rate” shall have the meaning assigned to such term in Section 2.2. 

“Note” means a Term Note. 
 “Patent License” means any written agreement granting any right with respect to any invention on which a Patent is in existence or a Patent application is pending, in which agreement Borrower
now holds or hereafter acquires any interest. 
 “Patents” means all letters patent of, or rights corresponding
thereto, in the United States or in any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United States or any other country. 

“Permitted Indebtedness” means: (i) Indebtedness of Borrower in favor of Lender arising under this Agreement or any other
Loan Document; (ii) Indebtedness existing on the Closing Date which is disclosed in Schedule 1A; (iii) Indebtedness of up to $5,000,000 outstanding at any time secured by a lien described in clause (vii) of the defined term
“Permitted Liens,” provided such Indebtedness does not exceed the lesser of the cost or fair market value (determined as of the date on which such Equipment is financed) of the Equipment financed with such Indebtedness;
(iv) Indebtedness to trade creditors incurred in the ordinary course of business, including Indebtedness incurred in the ordinary course of business with corporate credit cards; (v) Indebtedness that also constitutes a Permitted
Investment; (vi) Subordinated Indebtedness; (vii) reimbursement obligations in connection with letters of credit that are secured by cash or cash equivalents and issued on behalf of the Borrower or a Subsidiary thereof in an amount not to
exceed $200,000 at any time outstanding, (viii) other Indebtedness in an amount not to exceed $100,000 at any time outstanding, and (ix) extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the
principal amount is not increased or the terms modified to impose materially more burdensome terms upon Borrower or its Subsidiary, as the case may be. 
 “Permitted Injectable Rights Transfer” means the sale or other transfer by Borrower in a transaction approved by Borrower’s Board of Directors to Medicis Pharmaceutical Corporation
(“Medicis”) or another entity designated by Medicis and Borrower, on terms negotiated and agreed upon in good faith between the parties, of all or any portion of (i) any Biologic License Applications or other intellectual property
and/or know-how related to Injectable Products, provided that Borrower is granted a right of reference or license outside the Field of Use (as defined in the License Agreement entered into as of July 27, 2009 by and between Borrower and
Medicis) with respect to such Biologic License Applications, intellectual property and/or know-how; where “Injectable Product” means (i) products containing botulinum neurotoxin as the active ingredient and that are delivered by
injection; (ii) products 

  
 4 

 
incorporating an oligopeptide as the active ingredient and that are delivered by injection or to (iii) any improvements or line extensions to (i) or (ii). 

“Permitted Investment” means: (i) Investments existing on the Closing Date which are disclosed in Schedule 1B;
(ii) (a) marketable direct obligations issued or unconditionally guaranteed by the United States of America or any agency or any State thereof maturing within one year from the date of acquisition thereof, (b) commercial paper
maturing no more than one year from the date of creation thereof and currently having a rating of at least A-2 or P-2 from either Standard & Poor’s Corporation or Moody’s Investors Service, (c) certificates of deposit issued
by any bank with assets of at least $500,000,000 maturing no more than one year from the date of investment therein, and (d) money market accounts; (iii) repurchases of stock from former employees, directors, or consultants of Borrower
under the terms of applicable repurchase agreements at the original issuance price of such securities in an aggregate amount not to exceed $250,000 in any fiscal year, provided that no Event of Default has occurred, is continuing or would exist
after giving effect to the repurchases; (iv) Investments accepted in connection with Permitted Transfers; (v) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers
and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower’s business; (vi) Investments consisting of notes receivable of, or prepaid royalties and other
credit extensions, to customers and suppliers who are not affiliates, in the ordinary course of business, provided that this subparagraph (vi) shall not apply to Investments of Borrower in any Subsidiary; (vii) Investments consisting of
loans not involving the net transfer on a substantially contemporaneous basis of cash proceeds to employees, officers or directors relating to the purchase of capital stock of Borrower pursuant to employee stock purchase plans or other similar
agreements approved by Borrower’s Board of Directors; (viii) Investments consisting of travel advances and Investments consisting of employee relocation loans and other employee loans and advances not to exceed $50,000 in the aggregate
and, in each case, in the ordinary course of business; (ix) Investments in newly-formed Subsidiaries organized in the United States, provided that such Subsidiaries enter into a Joinder Agreement promptly after their formation by Borrower and
execute such other documents as shall be reasonably requested by Lender; (x) Investments in subsidiaries organized outside of the United States approved in advance in writing by Lender; (xi) joint ventures or strategic alliances in the
ordinary course of Borrower’s business consisting of the nonexclusive licensing of technology, the development of technology or the providing of technical support, provided that any cash Investments by Borrower do not exceed $1,000,000 in the
aggregate in any fiscal year; (xii) Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; (xiii) Investments in connection with mergers or
acquisitions permitted by Section 7.9; (xiv) Investments made pursuant to the conversion or settlement of convertible securities or debt of Borrower existing on the date hereof; and (xv) additional Investments that do not exceed
$500,000 in the aggregate. 
 “Permitted Liens” means any and all of the following: (i) Liens in favor of
Lender; (ii) Liens existing on the Closing Date which are disclosed in Schedule 1C; (iii) Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in good faith by appropriate
proceedings; provided, that Borrower maintains adequate reserves therefor in accordance with GAAP to the extent required by GAAP; (iv) Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and
other like Persons arising in the ordinary course of Borrower’s business and imposed without action of such parties; provided, that the payment thereof is not yet overdue; (v) Liens arising from judgments, decrees or attachments in
circumstances which do not constitute an Event of Default hereunder; (vi) the following deposits, to the extent made in the ordinary course of business: deposits under worker’s compensation, unemployment insurance, social security and
other similar laws, or to secure the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure indemnity, performance or other similar bonds for the performance of bids, tenders or contracts (other than
for the repayment of borrowed money) or to secure 

  
 5 

 
statutory obligations (other than liens arising under ERISA or environmental liens) or surety or appeal bonds, or to secure indemnity, performance or other similar bonds; (vii) Liens on
Equipment constituting purchase money liens and liens in connection with capital leases securing Indebtedness permitted in clause (iii) of “Permitted Indebtedness” with respect to such Equipment with a fair market value (determined as
of the date on which such Equipment is financed) not in excess of $5,000,000 outstanding at any time; (viii) Liens incurred in connection with Subordinated Indebtedness; (ix) leasehold interests in leases or subleases and licenses granted
in the ordinary course of business and not interfering in any material respect with the business of Borrower, and licenses permitted under Permitted Transfers; (x) Liens in favor of customs and revenue authorities arising as a matter of law to
secure payment of custom duties that are promptly paid on or before the date they become due; (xi) Liens on insurance proceeds securing the payment of financed insurance premiums that are promptly paid on or before the date they become due
(provided that such Liens extend only to such insurance proceeds and not to any other property or assets); (xii) statutory and common law rights of set-off and other similar rights as to deposits of cash and securities in favor of banks, other
depository institutions and brokerage firms; (xiii) easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the ordinary course of business so long as they do not materially impair
the value or marketability of the related property; (xiv) Liens on cash or cash equivalents securing obligations permitted under clause (vii) of the definition of Permitted Indebtedness; and (xv) Liens incurred in connection with the
extension, renewal or refinancing of the indebtedness secured by Liens of the type described in clauses (i) through (xi) above; provided, that any extension, renewal or replacement Lien shall be limited to the property encumbered by the
existing Lien and the principal amount of the indebtedness being extended, renewed or refinanced (as may have been reduced by any payment thereon) does not increase. 
 “Permitted Transfers” means (i) sales of Inventory in the normal course of business, (ii) non-exclusive and exclusive licenses and similar arrangements for the use of Intellectual
Property on commercially reasonable terms that could not result in a legal transfer of title of the licensed property, or (iii) dispositions of worn-out, obsolete or surplus Equipment at fair market value in the ordinary course of business,
(iv) dispositions expressly permitted under Section 7.7, 7.8 or 7.9, (v) dispositions arising from the abandonment of fixtures and other similar tenant improvements in connection with office relocations in the ordinary course of
business, (vi) other Transfers of assets having a fair market value of not more than $250,000 in the aggregate in any fiscal year and (vii) any Permitted Injectable Rights Transfers. 

“Person” means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization,
association, corporation, limited liability company, institution, other entity or government. 
 “Preferred Stock”
means at any given time any equity security issued by Borrower that has any rights, preferences or privileges senior to Borrower’s common stock. 
 “Prepayment Premium” means the amount achieved by multiplying the percentage in the table below by $15,000,000: 
  

					
	 If prepayment occurs prior to the first anniversary of the Closing Date
	  	 	4.00	% 
		
	 If prepayment occurs on or after the first anniversary, but prior to the second anniversary of the Closing Date
	  	 	3.00	% 

  
 6 

					
	 If prepayment occurs on or after the second anniversary, but prior to the third anniversary of the Closing Date
	  	 	2.00	% 
		
	 If prepayment occurs on or after the third anniversary, but prior to the fourth anniversary of the Closing Date
	  	 	1.00	% 

 “Principal Commencement Date” means July 1, 2012; provided, that (i) if
Borrower obtains at least $45,000,000 in cash proceeds from one or more Qualified Transactions that occur on or before December 31, 2011, such date shall be October 1, 2012; and (ii) if Borrower obtains at least $70,000,000 in cash
proceeds from one or more Qualified Transactions that occur on or before December 31, 2011, such date shall be January 1, 2013. 
 “Qualified Transaction” means an equity financing, strategic partnership or a combination thereof. 
 “Receivables” means (i) all of Borrower’s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, letters of credit, proceeds of any letter of credit, and Letter of
Credit Rights, and (ii) all customer lists, software, and business records related thereto. 
 “Secured
Obligations” means Borrower’s obligations under this Agreement and any Loan Document, including any obligation to pay any amount now owing or later arising. Notwithstanding the foregoing, the “Secured Obligations” shall not
include any of Borrower’s obligations, liabilities or duties under the Warrant. 
 “Subordinated Indebtedness”
means Indebtedness subordinated to the Secured Obligations in amounts and on terms and conditions satisfactory to Lender in its sole discretion. 
 “Subordination Agreement” means that certain subordination agreement among Borrower, Lender and Creditors (as defined therein) dated as of the date hereof. 

“Subsequent Financing” means the closing of any Borrower financing which becomes effective after the Closing Date and results
in aggregate proceeds to Borrower of at least $5,000,000. 
 “Subsidiary” means an entity, whether corporate,
partnership, limited liability company, joint venture or otherwise, in which Borrower owns or controls 50% or more of the outstanding voting securities, including each entity listed on Schedule 1 hereto. 

“Term Loan Advance” means the Term Loan funds advanced under this Agreement. 

“Term Loan Amount” means Twenty Two Million Dollars ($22,000,000). 

“Term Loan Interest Rate” means for any day a per annum rate of interest equal to the greater of (i) 9.85% or
(ii) the sum of 9.85%, plus the prime rate as reported in The Wall Street Journal minus 3.25%; provided that, if Borrower obtains at least $70,000,000 in cash proceeds from one or more Qualified Transactions that occur on or before
March 31, 2012, “Term Loan Interest Rate” shall mean, for any day (commencing with the closing date of such Qualified Transaction) a per annum rate of interest 

  
 7 

 
equal to the greater of (i) 8.50% or (ii) the sum of 8.50%, plus the prime rate as reported in The Wall Street Journal minus 3.25%. 

“Term Loan Maturity Date” means the date that is thirty-three (33) months from the Principal Commencement Date, which
date shall not occur prior to forty-two (42) or later than forty-eight (48) full calendar months from the Closing Date. 
 “Term Note” means the Promissory Note in substantially the form of Exhibit B. 
 “Trademark License” means any written agreement granting any right to use any Trademark or Trademark registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or
hereafter acquires any interest. 
 “Trademarks” means all trademarks (registered, common law or otherwise) and any
applications in connection therewith, including registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any
political subdivision thereof. 
 “UCC” means the Uniform Commercial Code as the same is, from time to time, in
effect in the State of California; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Lender’s Lien on any Collateral is governed by
the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other than the State of California, then the term “UCC” shall mean the Uniform Commercial Code as in effect, from time to time, in such other
jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions. 

“Warrant” means the Warrant Agreement entered into in connection with the Loan. 

Unless otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a “Section,”
“subsection,” “Exhibit,” “Annex,” or “Schedule” shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement. Unless otherwise specifically provided herein, any
accounting term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in accordance with GAAP, consistently applied.
Unless otherwise defined herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC. 

SECTION 2. THE LOAN 
 2.1 Term Loan. 
 (a) Advance. Subject to the terms and conditions
of this Agreement, Lender will make, and Borrower agrees to draw, a Term Loan Advance in the amount of the Term Loan Amount on the Closing Date. 
 (b) Advance Request. To obtain the Term Loan Advance, Borrower shall complete, sign and deliver an Advance Request and Term Note to Lender. Lender shall fund the Term Loan Advance in the manner requested
by the Advance Request provided that each of the conditions precedent to the Term Loan Advance is satisfied as of the requested Advance Date. 

  
 8 

 (c) Interest. The principal balance of the Term Loan Advance shall bear
interest thereon from the Advance Date at the Term Loan Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed. The Term Loan Interest Rate will float and change on the day the
prime rate changes from time to time. 
 (d) Payment. Borrower will pay interest on the Term Loan Advance on the
first day of each month, beginning the month after the Advance Date. Borrower shall repay the aggregate Term Loan principal balance that is outstanding in thirty-three (33) equal monthly installments of principal and interest beginning on the
Principal Commencement Date and continuing on the first business day of each month thereafter. The entire Term Loan principal balance and all accrued but unpaid interest hereunder, shall be due and payable on the Term Loan Maturity Date. Borrower
shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to the Borrower’s account as authorized on the ACH Authorization on each
payment date of all periodic obligations payable to Lender under the Term Note or Term Advance. 
 2.2 Maximum
Interest. Notwithstanding any provision in this Agreement, the Note, or any other Loan Document, it is the parties’ intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a
court of competent jurisdiction shall deem applicable hereto (which under the laws of the State of California shall be deemed to be the laws relating to permissible rates of interest on commercial loans) (the “Maximum Rate”). If a court of
competent jurisdiction shall finally determine that Borrower has actually paid to Lender an amount of interest in excess of the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum
Rate, then such excess interest actually paid by Borrower shall be applied as follows: first, to the payment of principal outstanding on the Note; second, after all principal is repaid, to the payment of Lender’s accrued and unpaid interest,
costs, expenses, professional fees and any other Secured Obligations; and third, after all Secured Obligations are repaid, the excess (if any) shall be refunded to Borrower. 

2.3 Default Interest. In the event any payment is not paid on the scheduled payment date, an amount equal to five percent
(5%) of the past due amount shall be payable on demand. In addition, upon the occurrence and during the continuation of an Event of Default hereunder, all Secured Obligations, including principal, interest, compounded interest, and
Lender’s fees and expenses set forth in Section 11.11, shall bear interest at a rate per annum equal to the rate set forth in Section 2.1(c) plus five percent (5%) per annum. In the event any interest is not paid when due
hereunder, delinquent interest shall be added to principal and shall bear interest on interest, compounded at the rate set forth in Section 2.1(c). 
 2.4 Prepayment. At its option upon at least 7 business days prior notice to Lender, Borrower may prepay all, but not less than all, of the outstanding Advance by paying the entire principal balance, all
accrued and unpaid interest, and the Prepayment Premium then applicable. 
 2.5 End of Term Charge. On the
earliest to occur of (i) the Term Loan Maturity Date, (ii) the date that Borrower prepays the outstanding Secured Obligations, or (iii) the date that the Secured Obligations become due and payable, Borrower shall pay Lender
(a) $500,000 as the end of term charge, or (b) if Borrower does not prepay the outstanding Secured Obligations or this Agreement is not otherwise terminated prior to the Maturity Date, Borrower shall only pay $400,000 as the end of term
charge. Notwithstanding the required payment date of such charge, it shall be deemed earned by Lender as of the Closing Date. 

  
 9 

 SECTION 3. SECURITY INTEREST 

3.1 As security for the prompt, complete and indefeasible payment when due (whether on the payment dates or otherwise) of
all the Secured Obligations, Borrower grants to Lender a security interest in all of Borrower’s right, title, and interest in and to the following personal property whether now owned or hereafter acquired (collectively, the
“Collateral”): (a) Receivables; (b) Equipment; (c) Fixtures; (d) General Intangibles; (e) Inventory; (f) Investment Property (but excluding thirty-five percent (35%) of the capital stock of any foreign
Subsidiary that constitutes a Permitted Investment); (g) Deposit Accounts; (h) Cash; (i) Goods; and all other tangible and intangible personal property of Borrower whether now or hereafter owned or existing, leased, consigned by or
to, or acquired by, Borrower and wherever located; and, to the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing.
Upon payment in full in cash of the Secured Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) and at such time as this Agreement has been
terminated, Lender shall, at Borrower’s sole cost and expense, release its Liens in the Collateral and all rights therein shall revert to Borrower. 
 SECTION 4. CONDITIONS PRECEDENT TO LOAN 
 The obligations of Lender
to make the Loan hereunder are subject to the satisfaction by Borrower of the following conditions: 
 4.1
Closing Conditions. On or prior to the Closing Date, Borrower shall have delivered to Lender the following: 

(a) executed originals of the Loan Documents, Account Control Agreements, a legal opinion of Borrower’s counsel, and
all other documents and instruments reasonably required by Lender to effectuate the transactions contemplated hereby and to create and perfect the Liens of Lender with respect to all Collateral, in all cases in form and substance reasonably
acceptable to Lender; 
 (b) certified copy of resolutions of Borrower’s board of directors evidencing
approval of (i) the Loan and other transactions evidenced by the Loan Documents; and (ii) the Warrant and transactions evidenced thereby; 
 (c) certified copy of resolutions of holders of a majority of the Series Preferred (as defined in the Certificate of Incorporation of Borrower), voting as a class, evidencing approval of the Loan and
other transactions evidenced by the Loan Documents; 
 (d) certified copies of the Certificate of Incorporation
and the Bylaws, as amended through the Closing Date, of Borrower; 
 (e) a certificate of good standing for
Borrower from its state of incorporation and similar certificates from all other jurisdictions in which it does business and where the failure to be qualified would have a Material Adverse Effect; 

(f) payment of the Facility Charge and reimbursement of Lender’s current expenses reimbursable pursuant to this
Agreement, which amounts may be deducted from the initial Advance; 

  
 10 

 (g) duly executed original signature to a payoff letter from Leader
Ventures, LLC, as agent, in form and substance reasonably acceptable to Lender; 
 (h) evidence that (i) the
Liens securing Indebtedness owed by Borrower to Leader Ventures, LLC, Leader Lending, LLC – Series A, Leader Lending, LLC – Series B, Silicon Valley Bank and Compass Horizon Funding Company, LLC will be terminated and (ii) the
documents and/or filings evidencing the perfection of such Liens, including without limitation any financing statements and/or control agreements, have or will, concurrently with the initial Advance, be terminated; and 

(i) such other documents as Lender may reasonably request. 

4.2 Advance. On the Advance Date: 
 (a) Lender shall have received (i) an Advance Request and the Note for the Advance as required by Section 2.1(b), each duly executed by Borrower’s Chief Executive Officer or Chief Financial
Officer, and (ii) any other documents Lender may reasonably request. 
 (b) The representations and
warranties set forth in this Agreement and in the Warrant shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and
warranties expressly relate to an earlier date. 
 (c) Borrower shall be in compliance with all the terms and
provisions set forth herein and in each other Loan Document on its part to be observed or performed, and at the time of and immediately after the Advance no Event of Default shall have occurred and be continuing. 

(d) The Advance Request shall be deemed to constitute a representation and warranty by Borrower on the Advance Date as to
the matters specified in paragraphs (b) and (c) of this Section 4.2 and as to the matters set forth in the Advance Request. 
 4.3 No Default. As of the Closing Date and the Advance Date, (i) no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of
Default and (ii) no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing. 
 SECTION 5. REPRESENTATIONS AND WARRANTIES OF BORROWER 
 Borrower
represents and warrants that: 
 5.1 Corporate Status. Borrower is a corporation duly organized, legally existing
and in good standing under the laws of the State of Delaware, and is duly qualified as a foreign corporation in all jurisdictions in which the nature of its business or location of its properties require such qualifications and where the failure to
be qualified could reasonably be expected to have a Material Adverse Effect. Borrower’s present name, former names (if any), locations, place of formation, tax identification number, organizational identification number and other information
are correctly set forth in Exhibit C, as may be updated by Borrower in a written notice (including any Compliance Certificate) provided to Lender after the Closing Date. 

  
 11 

 5.2 Collateral. Borrower owns the Collateral, free of all Liens, except for
Permitted Liens. Borrower has the power and authority to grant to Lender a Lien in the Collateral as security for the Secured Obligations. 
 5.3 Consents. Borrower’s execution, delivery and performance of the Note, this Agreement and all other Loan Documents, and Borrower’s execution of the Warrant, (i) have been duly authorized
by all necessary corporate action of Borrower, (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than Permitted Liens and the Liens created by this Agreement and the other Loan Documents, (iii) do
not violate any provisions of Borrower’s Certificate of Incorporation, bylaws, or any, law, regulation, order, injunction, judgment, decree or writ to which Borrower is subject and (iv) except as described on Schedule 5.3, do not violate
any contract or agreement or require the consent or approval of any other Person. The individual or individuals executing the Loan Documents are duly authorized to do so. 

5.4 Material Adverse Effect. 
 (a) Since December 31, 2008, no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing. 

(b) As of the Closing Date, Borrower is not aware of any event likely to occur that is reasonably expected to result in a
Material Adverse Effect. 
 5.5 Actions Before Governmental Authorities. Except as described on Schedule 5.5,
there are no actions, suits or proceedings at law or in equity or by or before any governmental authority now pending or, to the knowledge of Borrower, threatened against or affecting Borrower or its property. 

5.6 Laws. Borrower is not in violation of any law, rule or regulation, or in default with respect to any judgment, writ,
injunction or decree of any governmental authority, where such violation or default is reasonably expected to result in a Material Adverse Effect. Borrower is not in default in any manner under any provision of any agreement or instrument evidencing
indebtedness, or any other material agreement to which it is a party or by which it is bound. 
 5.7 Information
Correct and Current. No information, report, Advance Request, financial statement, exhibit or schedule furnished, by or on behalf of Borrower to Lender in connection with any Loan Document or included therein or delivered pursuant thereto contained,
contains or will contain any material misstatement of fact or omitted, omits or will omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were, are or will be made, not
misleading at the time such statement was made or deemed made. Additionally, any and all financial or business projections provided by Borrower to Lender shall be (i) provided in good faith and based on the most current data and information
available to Borrower, and (ii) the most current of such projections approved by Borrower’s Board of Directors. 
 5.8 Tax Matters. Except as described on Schedule 5.8, (a) Borrower has filed all federal, and all material state and local tax returns that it is required to file, (b) Borrower has duly paid or
fully reserved for all taxes or installments thereof (including any interest or penalties) as and when due, which have or may become due pursuant to such returns, and (c) Borrower has paid or fully reserved for any tax assessment received by
Borrower for the three (3) years preceding the Closing Date, if any (including any taxes being contested in good faith and by appropriate proceedings). 

  
 12 

 5.9 Intellectual Property Claims. Borrower is the sole owner of, or
otherwise has the right to use, the Intellectual Property. Except as described on Schedule 5.9,(i) each of the material Copyrights, Trademarks and Patents is valid and enforceable, (ii) no material part of the Intellectual Property has been
judged invalid or unenforceable, in whole or in part, and (iii) no claim has been made to Borrower that any material part of the Intellectual Property violates the rights of any third party. Exhibit D is a true, correct and complete list
of each of Borrower’s Patents, registered Trademarks, registered Copyrights, and material agreements under which Borrower licenses Intellectual Property from third parties (other than shrink-wrap software licenses), together with application or
registration numbers, as applicable, owned by Borrower or any Subsidiary, in each case as of the Closing Date. Borrower is not in material breach of, nor has Borrower failed to perform any material obligations under, any of the foregoing contracts,
licenses or agreements and, to Borrower’s knowledge, no third party to any such contract, license or agreement is in material breach thereof or has failed to perform any material obligations thereunder. 

5.10 Intellectual Property. Except as described on Schedule 5.10, Borrower has, or in the case of any proposed business,
will have, all material rights with respect to Intellectual Property necessary in the operation or conduct of Borrower’s business as currently conducted and proposed to be conducted by Borrower. Without limiting the generality of the foregoing,
and in the case of Licenses, except for restrictions that are unenforceable under Division 9 of the UCC, Borrower has the right, to the extent required to operate Borrower’s business, to freely transfer, license or assign Intellectual Property
without condition, restriction or payment of any kind (other than license payments in the ordinary course of business) to any third party, and Borrower owns or has the right to use, pursuant to valid licenses, all software development tools, library
functions, compilers and all other third-party software and other items that are used in the design, development, promotion, sale, license, manufacture, import, export, use or distribution of Borrower Products. 

5.11 Borrower Products. Except as described on Schedule 5.11, no Intellectual Property owned by Borrower or Borrower
Product has been or is subject to any actual or, to the knowledge of Borrower, threatened litigation, proceeding (including any proceeding in the United States Patent and Trademark Office or any corresponding foreign office or agency) or outstanding
decree, order, judgment, settlement agreement or stipulation that restricts in any manner Borrower’s use, transfer or licensing thereof or that may affect the validity, use or enforceability thereof. There is no decree, order, judgment,
agreement, stipulation, arbitral award or other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant licenses or ownership interest in any future Intellectual Property related to the operation or
conduct of the business of Borrower or Borrower Products. Borrower has not received any written notice or claim, or, to the knowledge of Borrower, oral notice or claim, challenging or questioning Borrower’s ownership in any Intellectual
Property (or written notice of any claim challenging or questioning the ownership in any licensed Intellectual Property of the owner thereof) or suggesting that any third party has any claim of legal or beneficial ownership with respect thereto nor,
to Borrower’s knowledge, is there a reasonable basis for any such claim. Neither Borrower’s use of its Intellectual Property nor the production and sale of Borrower Products infringes the Intellectual Property or other rights of others.

 5.12 Financial Accounts. Exhibit E, as may be updated by the Borrower in a written notice provided to Lender
after the Closing Date, is a true, correct and complete list of (a) all banks and other financial institutions at which Borrower or any Subsidiary maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary
maintains an account holding Investment Property, and such exhibit correctly identifies the name, address and telephone number of each bank or other institution, the name in which the account is held, a description of the purpose of the account, and
the complete account number therefor. 

  
 13 

 5.13 Employee Loans. Borrower has no outstanding loans to any employee,
officer or director of the Borrower nor has Borrower guaranteed the payment of any loan made to an employee, officer or director of the Borrower by a third party. 

5.14 Capitalization and Subsidiaries. Borrower’s capitalization as of the Closing Date is set forth on Schedule 5.14
annexed hereto. Borrower does not own any stock, partnership interest or other securities of any Person, except for Permitted Investments. Attached as Schedule 5.14, as may be updated by Borrower in a written notice provided after the Closing Date,
is a true, correct and complete list of each Subsidiary. 
 SECTION 6. INSURANCE; INDEMNIFICATION 

6.1 Coverage. Borrower shall cause to be carried and maintained commercial general liability insurance, on an occurrence
form, against risks customarily insured against in Borrower’s line of business. Such risks shall include the risks of bodily injury, including death, property damage, personal injury, advertising injury, and contractual liability per the terms
of the indemnification agreement found in Section 6.3. Borrower must maintain a minimum of $1,000,000 of commercial general liability insurance for each occurrence and $2,000,000 in the aggregate, and products liability insurance of not less
than $1,000,000. Borrower has and agrees to maintain a minimum of $1,000,000 of director’s and officers’ insurance for each occurrence and $1,000,000 in the aggregate. So long as there are any Secured Obligations (other than inchoate
indemnity obligations) outstanding, Borrower shall also cause to be carried and maintained insurance upon the Collateral, insuring against all risks of physical loss or damage howsoever caused, in an amount not less than the full replacement cost of
the Collateral, provided that such insurance may be subject to standard exceptions and deductibles. 
 6.2
Certificates. Borrower shall deliver to Lender certificates of insurance that evidence Borrower’s compliance with its insurance obligations in Section 6.1 and the obligations contained in this Section 6.2. Borrower’s insurance
certificate shall state Lender is an additional insured for commercial general liability, an additional insured and a loss payee for all risk property damage insurance. Attached to the certificates of insurance will be additional insured
endorsements for liability and lender’s loss payable endorsements, or copies of policy forms evidencing Lender as additional assured or lender loss payee, as applicable, for all risk property damage insurance. All certificates of insurance will
provide for a minimum of thirty (30) days advance written notice to Lender of cancellation. Any failure of Lender to scrutinize such insurance certificates for compliance is not a waiver of any of Lender’s rights, all of which are
reserved. 
 6.3 Indemnity. Borrower agrees to indemnify and hold Lender and its officers, directors, employees,
agents, in-house attorneys, representatives and shareholders harmless from and against any and all claims, costs, expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities based on liability in tort,
including strict liability in tort), including reasonable attorneys’ fees and disbursements and other costs of investigation or defense (including those incurred upon any appeal), that may be instituted or asserted against or incurred by Lender
or any such Person as the result of credit having been extended, suspended or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection with or arising out of the transactions contemplated
hereunder and thereunder, or any actions or failures to act in connection therewith, or arising out of the disposition or utilization of the Collateral, excluding in all cases claims resulting solely from Lender’s gross negligence or willful
misconduct. Borrower agrees to pay, and to save Lender harmless from, any and all liabilities with respect to, or resulting from any delay in paying, any and all excise, sales or other 

  
 14 

 
similar taxes (excluding taxes imposed on or measured by the net income of Lender) that may be payable or determined to be payable with respect to any of the Collateral or this Agreement.

 SECTION 7. COVENANTS OF BORROWER 
 Borrower agrees as follows: 
 7.1 Financial Reports. Borrower shall
furnish to Lender the financial statements and reports listed hereinafter (the “Financial Statements”): 
 (a) as soon as practicable (and in any event within 30 days) after the end of each month, unaudited interim and year-to-date financial statements as of the end of such month (prepared on a consolidated
and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against
Borrower) or any other occurrence that would reasonably be expected to have a Material Adverse Effect, all certified by Borrower’s Chief Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance with
GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year end adjustments, and (iii) they do not contain certain non-cash items that are customarily included in quarterly and annual financial statements;

 (b) as soon as practicable (and in any event within 30 days) after the end of each calendar quarter, unaudited
interim and year-to-date financial statements as of the end of such calendar quarter (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows accompanied by a report
detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that would reasonably be expected to have a Material Adverse Effect, certified by Borrower’s Chief
Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, and (ii) that they are subject to normal year end adjustments; as well as the most
recent capitalization table for Borrower, including the weighted average exercise price of employee stock options; 
 (c) as soon as practicable (and in any event within two hundred and seventy (270) days) after the end of each fiscal year, unqualified audited financial statements as of the end of such year
(prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal year, certified by
a firm of independent certified public accountants selected by Borrower and reasonably acceptable to Lender, accompanied by any management report from such accountants; 

(d) as soon as practicable (and in any event within 30 days) after the end of each month, a Compliance Certificate in the
form of Exhibit F; 
 (e) as soon as practicable (and in any event within 30 days) after the end of each month, a
report showing agings of accounts receivable and accounts payable; 
 (f) promptly after the sending or filing
thereof, as the case may be, copies of any proxy statements, financial statements or reports that Borrower has made available to holders of its Preferred Stock and copies of any regular, periodic and special reports or registration

  
 15 

 
statements that Borrower files with the Securities and Exchange Commission or any governmental authority that may be substituted therefor, or any national securities exchange; 

(g) at the same time and in the same manner as it gives to its directors (and in any event quarterly), copies of all
notices, minutes, consents and other materials that Borrower provides to its directors in connection with meetings of the Board of Directors, minutes of such meeting; provided that Borrower shall not be required to deliver (i) confidential or
privileged information, (ii) executive session materials; and (iii) information relating to any conflict of interest policy; and 
 (h) financial and business projections promptly following their approval by Borrower’s Board of Directors, as well as budgets, operating plans and other financial information reasonably requested by
Lender. 
 Borrower shall not (without the consent of Lender, such consent not to be unreasonably withheld or delayed), make any
change in its (a) accounting policies or reporting practices, except to the extent that such changes are in conformity with GAAP or (b) fiscal years or fiscal quarters. The fiscal year of Borrower shall end on December 31. 

The executed Compliance Certificate may be sent via facsimile to Lender at (650) 473-9194 or via e-mail to kconte@herculestech.com.
All Financial Statements required to be delivered pursuant to clauses (a), (b) and (c) shall be sent via e-mail to financialstatements@herculestech.com with a copy to kconte@herculestech.com provided, that if e-mail is not available
or sending such Financial Statements via e-mail is not possible, they shall be sent via facsimile to Lender at: (866) 468-8916, attention Chief Credit Officer. 

7.2 Management Rights. Borrower shall permit any representative that Lender authorizes, including its attorneys and
accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of Borrower at reasonable times and upon reasonable notice during normal business hours. Such inspections or examinations shall be
conducted no more often than once every six months unless an Event of Default has occurred and is continuing. In addition, any such representative shall have the right to meet with management and officers of Borrower to discuss such books of account
and records. In addition, Lender shall be entitled at reasonable times and intervals to consult with and advise the management and officers of Borrower concerning significant business issues affecting Borrower. Such consultations shall not
unreasonably interfere with Borrower’s business operations. The parties intend that the rights granted Lender shall constitute “management rights” within the meaning of 29 C.F.R Section 2510.3-101(d)(3)(ii), but that any advice,
recommendations or participation by Lender with respect to any business issues shall not be deemed to give Lender, nor be deemed an exercise by Lender of, control over Borrower’s management or policies. 

7.3 Further Assurances. Borrower shall from time to time execute, deliver and file, alone or with Lender, any financing
statements, security agreements, collateral assignments, notices, control agreements, or other documents to perfect or give the highest priority to Lender’s Lien on the Collateral. Borrower shall from time to time procure any instruments or
documents as may be requested by Lender, and take all further action that may be necessary or desirable, or that Lender may reasonably request, to perfect and protect the Liens granted hereby and thereby. In addition, and for such purposes only,
Borrower hereby authorizes Lender to execute and deliver on behalf of Borrower and to file such financing statements, collateral assignments, notices, control agreements, security agreements and other documents without the signature of Borrower
either in Lender’s name or in the name of Lender as agent and attorney-in-fact for Borrower. Borrower shall 

  
 16 

 
protect and defend Borrower’s title to the Collateral and Lender’s Lien thereon against all Persons claiming any interest adverse to Borrower or Lender other than Permitted Liens.

 7.4 Indebtedness. Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to
any Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness, except for the conversion of Indebtedness into
equity securities and the payment of cash in lieu of fractional shares in connection with such conversion. 
 7.5
Collateral. Borrower shall at all times keep the Collateral, the Intellectual Property and all other property and assets used in Borrower’s business or in which Borrower now or hereafter holds any interest free and clear from any legal process
or Liens whatsoever (except for Permitted Liens), and shall give Lender prompt written notice of any legal process affecting the Collateral, the Intellectual Property, such other property and assets, or any Liens thereon. Borrower shall cause its
Subsidiaries to protect and defend such Subsidiary’s title to its assets from and against all Persons claiming any interest adverse to such Subsidiary, and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary’s
property and assets free and clear from any legal process or Liens whatsoever (except for Permitted Liens), and shall give Lender prompt written notice of any legal process affecting such Subsidiary’s assets. Except with respect to
(i) specific property encumbered to secure payment of particular Indebtedness and (ii) restrictions by reason of customary provisions restricting assignments, subletting or other transfers contained in leases, licenses and similar
agreements entered into in the ordinary course of business (provided that such restrictions are limited to the property or assets secured by such Liens or the property or assets subject to such leases, licenses or similar agreements, as the case may
be), Borrower shall not agree with any Person other than Lender to encumber its property, except for Permitted Liens. Borrower shall not agree with any Person other than Lender not to encumber its property. 

7.6 Investments. Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person, or
permit any of its Subsidiaries so to do, other than Permitted Investments. 
 7.7 Distributions. Borrower shall
not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class of stock or other equity interest other than pursuant to employee, director or consultant repurchase plans or other similar agreements, provided, however, in each
case the repurchase or redemption price does not exceed the original consideration paid for such stock or equity interest, or (b) declare or pay any cash dividend or make a cash distribution on any class of stock or other equity interest,
except that a Subsidiary may pay dividends or make distributions to Borrower, or (c) lend money to any employees, officers or directors or guarantee the payment of any such loans granted by a third party except as expressly permitted by clause
(viii) of the definition of Permitted Investments or (d) waive, release or forgive any indebtedness owed by any employees, officers or directors other than Indebtedness expressly permitted by clause (viii) of the definition of
Permitted Investments. 
 7.8 Transfers. Except for Permitted Transfers, Borrower shall not voluntarily or
involuntarily transfer, sell, lease, license, lend or in any other manner convey any equitable, beneficial or legal interest in any material portion of their assets. 

7.9 Mergers or Acquisitions. Borrower shall not merge or consolidate, or permit any of its Subsidiaries to merge or
consolidate, with or into any other business organization (other than mergers or consolidations of a Subsidiary into another Subsidiary or into Borrower), or acquire, or 

  
 17 

 
permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person. 

7.10 Taxes. Borrower and its Subsidiaries shall pay when due all taxes, fees or other charges of any nature whatsoever
(together with any related interest or penalties) now or hereafter imposed or assessed against Borrower, Lender (assessed in connection with the making of the Loan hereunder but excluding any taxes on Lender’s net income) or the Collateral or
upon Borrower’s ownership, possession, use, operation or disposition thereof or upon Borrower’s rents, receipts or earnings arising therefrom. Borrower shall file on or before the due date therefor all personal property tax returns in
respect of the Collateral. Notwithstanding the foregoing, Borrower may contest, in good faith and by appropriate proceedings, taxes for which Borrower maintains adequate reserves therefor in accordance with GAAP. 

7.11 Corporate Changes. Neither Borrower nor any Subsidiary shall change its corporate name, legal form or jurisdiction of
formation without twenty (20) days’ prior written notice to Lender. Neither Borrower nor any Subsidiary shall suffer a Change in Control. Neither Borrower nor any Subsidiary shall relocate its chief executive office or its principal place
of business unless: (i) it has provided prior written notice to Lender; and (ii) such relocation shall be within the continental United States. Neither Borrower nor any Subsidiary shall relocate any item of Collateral (other than
(w) sales of Inventory in the ordinary course of business, (x) relocations of mobile Equipment, (y) relocations of Equipment having an aggregate value of up to $150,000 in any fiscal year, and (z) relocations of Collateral from a
location described on Exhibit C to another location described on Exhibit C) unless (i) it has provided prompt written notice to Lender, (ii) such relocation is within the continental United States or to such other jurisdiction as
designated in writing by Borrower from time to time, and, (iii) if such relocation is to a third party bailee, it has delivered a bailee agreement in form and substance reasonably acceptable to Lender. 

7.12 Deposit Accounts. Neither Borrower nor any Subsidiary shall maintain any Deposit Accounts, or accounts holding
Investment Property, except with respect to which Lender has an Account Control Agreement. 
 7.13 Borrower shall
notify Lender of each Subsidiary formed subsequent to the Closing Date and, within 30 days of formation, shall cause any such Subsidiary organized under the laws of any State within the United States to execute and deliver to Lender a Joinder
Agreement. 
 SECTION 8. RIGHT TO INVEST OR CONVERT 

8.1 Lender or its assignee or nominee shall have the right, in its discretion, to participate in the next Subsequent
Financing in an amount of up to $1,000,000 on the same terms, conditions and pricing afforded to others participating in such Subsequent Financing; provided, however, that the obligation of the Borrower to issue and sell to Lender any equity
securities pursuant to this Section 8.1 is subject in all cases to the preparation, execution and delivery by the Borrower and Lender of a purchase agreement containing the same terms and conditions set forth in the agreement between the
Borrower and other investors participating in such Subsequent Financing, if any, and other terms and conditions reasonable acceptable to the Borrower and Lender, and the receipt of any required regulatory approval. Borrower shall provide notice to
Lender of the next Subsequent Financing, and Lender shall have 10 business days from the date of receipt of such notice to elect to participate in the next Subsequent Financing; provided, further, that if Lender or its assignee or nominee elects to
participate in the next Subsequent Financing, but through no fault of its own is unable to participate, either with respect to all or a portion of the amount it requests to invest, Lender or its assignee or nominee shall have the right to invest the

  
 18 

 
remainder of the $1,000,000 in the Subsequent Financing occurring after the next Subsequent Financing (the “Second Subsequent Financing”). For the avoidance of doubt, if Lender or its
assignee does not choose to invest in the next Subsequent Financing, Lender shall have no right to participate in any future equity or other financing of Borrower occurring after the next Subsequent Financing; and if Lender has a right to invest in
the Second Subsequent Financing pursuant to the foregoing, and chooses not to participate in the Second Subsequent Financing, then Lender shall have no right to participate in any future equity or other financing of Borrower following such Second
Subsequent Financing. The closing of Lender’s participation shall be concurrent with the closing of each such Subsequent Financing, as applicable. 
 8.2 Lender or its assignee or nominee shall have the right, in its discretion and subject to consent by Borrower which shall not be unreasonably withheld, to participate in the next Subsequent Financing
by converting up to $1,000,000 of the Term Loan Advance on the same terms, conditions and pricing afforded to others participating in the next such Subsequent Financing; provided, however, that such conversion pursuant to this Section 8.2 is
subject in all cases to the preparation, execution and delivery by the Borrower and Lender of a purchase agreement (or conversion or similar agreement) containing the same terms and conditions set forth in the agreement between the Borrower and
other investors participating in the applicable Subsequent Financing, if any, and other terms and conditions reasonable acceptable to the Borrower and Lender, and the receipt of any required regulatory approval. For the avoidance of doubt, the
closing of Lender’s conversion shall be concurrent with the closing of the Subsequent Financing. 
 SECTION 9.
EVENTS OF DEFAULT 
 The occurrence of any one or more of the following events shall be an Event of Default:

 9.1 Payments. Borrower fails to pay any amount due under this Agreement, the Note or any of the other Loan
Documents on the due date; or 
 9.2 Covenants. Borrower breaches or defaults in the performance of any covenant
or Secured Obligation under this Agreement, the Note, or any of the other Loan Documents, and (a) with respect to a default under any covenant under this Agreement (other than under Sections 6, 7.4, 7.5, 7.6, 7.7, 7.8 or 7.9) such default
continues for more than ten (10) days after the earlier of the date on which (i) Lender has given notice of such default to Borrower and (ii) Borrower has actual knowledge of such default or (b) with respect to a default under
any of Sections 6, 7.4, 7.5, 7.6, 7.7, 7.8 or 7.9, the occurrence of such default; or 
 9.3 Material Adverse
Effect. A circumstance has occurred that would reasonably be expected to have a Material Adverse Effect; or 

9.4 Other Loan Documents. The occurrence of any default under any Loan Document or any other agreement between Borrower
and Lender and such default continues for more than ten (10) days after the earlier of the date on which (a) Lender has given notice of such default to Borrower, or (b) Borrower has actual knowledge of such default; or 

9.5 Representations. Any representation or warranty made by Borrower in any Loan Document or in the Warrant shall have
been false or misleading in any material respect; or 
 9.6 Insolvency. Borrower (A) (i) shall make an
assignment for the benefit of creditors; or (ii) shall be unable to pay its debts as they become due, or be unable to pay or perform under the Loan Documents, or shall become insolvent; or (iii) shall file a voluntary petition in
bankruptcy; or 

  
 19 

 
(iv) shall file any petition, answer, or document seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present
or future statute, law or regulation pertinent to such circumstances; or (v) shall seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of Borrower or of all or any substantial part (i.e., 33-1/3% or more)
of the assets or property of Borrower; or (vi) shall cease operations of its business as its business has normally been conducted, or terminate substantially all of its employees; or (vii) Borrower or its directors or majority shareholders
shall take any action initiating any of the foregoing actions described in clauses (i) through (vi); or (B) either (i) forty-five (45) days shall have expired after the commencement of an involuntary action against Borrower
seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, without such action being dismissed or all orders or proceedings thereunder affecting
the operations or the business of Borrower being stayed; or (ii) a stay of any such order or proceedings shall thereafter be set aside and the action setting it aside shall not be timely appealed; or (iii) Borrower shall file any answer
admitting or not contesting the material allegations of a petition filed against Borrower in any such proceedings; or (iv) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such
proceedings; or (v) forty-five (45) days shall have expired after the appointment, without the consent or acquiescence of Borrower, of any trustee, receiver or liquidator of Borrower or of all or any substantial part of the properties of
Borrower without such appointment being vacated; or 
 9.7 Attachments; Judgments. Any portion of Borrower’s
assets is attached or seized, or a levy is filed against any such assets, or a judgment or judgments is/are entered for the payment of money, individually or in the aggregate, of at least $250,000 and such judgment remains unstayed for a period of
ten (10) days, or Borrower is enjoined or in any way prevented by court order from conducting any part of its business; or 
 9.8 Other Obligations. The occurrence of any default under any agreement or obligation of Borrower involving any Indebtedness which results in a right by a third party or parties, whether or not
exercised, to accelerate the maturity of such Indebtedness in excess of $200,000, or the occurrence of any default under any agreement or obligation of Borrower that could reasonably be expected to have a Material Adverse Effect. 

SECTION 10. REMEDIES 
 10.1 General. Upon and during the continuance of any one or more Events of Default, (i) Lender may, at its option, accelerate and demand payment of all or any part of the Secured Obligations and
declare them to be immediately due and payable (provided, that upon the occurrence of an Event of Default of the type described in Section 9.6, the Note and all of the Secured Obligations shall automatically be accelerated and made due and
payable, in each case without any further notice or act), and (ii) Lender may notify any of Borrower’s account debtors to make payment directly to Lender, compromise the amount of any such account on Borrower’s behalf and endorse
Lender’s name without recourse on any such payment for deposit directly to Lender’s account. Lender may exercise all rights and remedies with respect to the Collateral under the Loan Documents or otherwise available to it under the UCC and
other applicable law, including the right to release, hold, sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy, utilize, process and commingle the Collateral. All
Lender’s rights and remedies shall be cumulative and not exclusive. 
 10.2 Collection; Foreclosure. Upon
the occurrence and during the continuance of any Event of Default, Lender may, at any time or from time to time, apply, collect, liquidate, sell in one 

  
 20 

 
or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable preparation or processing, in such order as Lender may
elect. Any such sale may be made either at public or private sale at its place of business or elsewhere. Borrower agrees that any such public or private sale may occur upon ten (10) calendar days’ prior written notice to Borrower. Lender
may require Borrower to assemble the Collateral and make it available to Lender at a place designated by Lender that is reasonably convenient to Lender and Borrower. The proceeds of any sale, disposition or other realization upon all or any part of
the Collateral shall be applied by Lender in the following order of priorities: 
 First, to Lender in an amount sufficient to
pay in full Lender’s costs and professionals’ and advisors’ fees and expenses as described in Section 11.11; 
 Second, to Lender in an amount equal to the then unpaid amount of the Secured Obligations (including principal, interest, and the Default Rate interest), in such order and priority as Lender may choose in
its sole discretion; and 
 Finally, after the full, final, and indefeasible payment in Cash of all of the Secured Obligations,
to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives or as a court of competent jurisdiction may direct. 
 Lender shall be deemed to have acted reasonably in the custody, preservation and disposition of any of the Collateral if it complies with the obligations of a secured party under the UCC. 

10.3 No Waiver. Lender shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or any
other Person, and Borrower expressly waives all rights, if any, to require Lender to marshal any Collateral. 

10.4 Cumulative Remedies. The rights, powers and remedies of Lender hereunder shall be in addition to all rights, powers
and remedies given by statute or rule of law and are cumulative. The exercise of any one or more of the rights, powers and remedies provided herein shall not be construed as a waiver of or election of remedies with respect to any other rights,
powers and remedies of Lender. 
 10.5 Medicis Option. Notwithstanding anything in this Agreement or any of the
Loan Documents, (i) prior to the Lender taking any action to foreclose pursuant to Sections 10.1 and 10.2 hereof on any Collateral following the occurrence of an Event of Default under Section 9 (other than Section 9.6(A)(i), (iii),
(iv) and (v), or Section 9.6(A)(vii) only with respect to clauses (i), (iii), (iv) and (v) of Section 9.6A, or Section 9.6(B), collectively, the “Insolvency Clauses”) of the Agreement, or (ii) upon the
occurrence of an Event of Default under any of the Insolvency Clauses, in either case Medicis has a ten (10) day option following the receipt of a written notice contemplated by the next sentence to acquire the loans outstanding under this
Agreement by making payment in lawful money of the United States of America to the Lender in an aggregate amount equal to all the outstanding obligations owed to the Lender under this Agreement. The Lender shall provide Medicis written notice at
least ten (10) days prior to the Lender taking any foreclosure action in the case of clause (i) of the preceding sentence, or promptly following the occurrence of an Event of Default under any of the Insolvency Clauses, in the case of
clause (ii) of the preceding sentence. In the event Medicis acquires the loans outstanding under this Agreement pursuant to this Section 10.5, the Lender shall assign, transfer and endorse its rights hereunder and under the Loan Documents
to Medicis in accordance with Section 11.7. The parties agree that Medicis is an intended third party beneficiary of this Section 10.5. Medicis’ right under this Section 10.5 shall terminate upon the termination of that certain
Option Agreement by and between Borrower and Medicis dated as of December 11, 2007. 

  
 21 

 SECTION 11. MISCELLANEOUS 

11.1 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without
invalidating the remainder of such provision or the remaining provisions of this Agreement. 
 11.2 Notice.
Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication (including the delivery of Financial Statements) that is required, contemplated, or permitted under the Loan
Documents or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission by facsimile or hand delivery or
delivery by an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid, in each case addressed to the party to be notified as
follows: 
  

	 	(a)	If to Lender: 

 HERCULES
TECHNOLOGY GROWTH CAPITAL, INC. 
 Legal Department 
 Attention: Chief Legal Officer and Kathy Conte 
 400 Hamilton Avenue, Suite 310

 Palo Alto, CA 94301 
 Facsimile: 650-473-9194 
 Telephone: 650-289-3060 

 

	 	(b)	If to Borrower: 

 REVANCE
THERAPEUTICS, INC. 
 Attention: Chief Financial Officer 

7555 Gateway Boulevard 
 Newark, California 94560 
 Facsimile: 510-742-3401 

Telephone: 510-742-3400 
  

	 	(c)	If to Medicis (with respect to Section 10.5): 

 Medicis Pharmaceutical Corporation 
 720 North Dobson Road 

Scottsdale, AZ 85256 
 Facsimile: (602) 808-0822 
 or to such other address as each party may
designate for itself by like notice. 
 11.3 Entire Agreement; Amendments. This Agreement, the Note, and the
other Loan Documents constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or
other documents or agreements, whether written or oral, with respect to the subject matter hereof or thereof (including Lender’s proposal letter dated July 7, 

  
 22 

 
2011). None of the terms of this Agreement, the Note or any of the other Loan Documents may be amended except by an instrument executed by each of the parties hereto. 

11.4 No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this
Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by
virtue of the authorship of any provisions of this Agreement. 
 11.5 No Waiver. The powers conferred upon Lender
by this Agreement are solely to protect its rights hereunder and under the other Loan Documents and its interest in the Collateral and shall not impose any duty upon Lender to exercise any such powers. No omission or delay by Lender at any time to
enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver of any such right or remedy to which Lender is entitled, nor shall it in
any way affect the right of Lender to enforce such provisions thereafter. 
 11.6 Survival. All agreements,
representations and warranties contained in this Agreement, the Note and the other Loan Documents or in any document delivered pursuant hereto or thereto shall be for the benefit of Lender and shall survive the execution and delivery of this
Agreement and the expiration or other termination of this Agreement. 
 11.7 Successors and Assigns. The
provisions of this Agreement and the other Loan Documents shall inure to the benefit of and be binding on Borrower and its permitted assigns (if any). Borrower shall not assign its obligations under this Agreement, the Note or any of the other Loan
Documents without Lender’s express prior written consent, and any such attempted assignment without such consent shall be void and of no effect. Subject to Section 11.13, Lender may assign, transfer, or endorse its rights hereunder and
under the other Loan Documents without prior notice to Borrower, and all of such rights shall inure to the benefit of Lender’s successors and assigns. 
 11.8 Governing Law. This Agreement, the Note and the other Loan Documents have been negotiated and delivered to Lender in the State of California, and shall have been accepted by Lender in the State of
California. Payment to Lender by Borrower of the Secured Obligations is due in the State of California. This Agreement, the Note and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State
of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 
 11.9 Consent to Jurisdiction and Venue. All judicial proceedings (to the extent that the reference requirement of Section 11.10 is not applicable) arising in or under or related to this Agreement,
the Note or any of the other Loan Documents may be brought in any state or federal court located in the State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to
nonexclusive personal jurisdiction in Santa Clara County, State of California; (b) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense based on lack of
jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement, the Note or the other Loan Documents. Service of process on any party hereto in any action
arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 11.2, and shall be deemed effective and received as set forth in Section 11.2. Nothing herein
shall affect the right 

  
 23 

 
to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. 

11.10 Mutual Waiver of Jury Trial / Judicial Reference. 

(a) Because disputes arising in connection with complex financial transactions are most quickly and economically resolved
by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF BORROWER AND
LENDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY BORROWER AGAINST LENDER OR ITS ASSIGNEE
OR BY LENDER OR ITS ASSIGNEE AGAINST BORROWER. This waiver extends to all such Claims, including Claims that involve Persons other than Borrower and Lender; Claims that arise out of or are in any way connected to the relationship between Borrower
and Lender; and any Claims for damages, breach of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other Loan Document. 

(b) If the waiver of jury trial set forth in Section 11.10(a) is ineffective or unenforceable, the parties agree that
all Claims shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a mutually acceptable referee or, if the parties cannot agree, a referee selected by the Presiding
Judge of the Santa Clara County, California. Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable to such proceeding. 

(c) In the event Claims are to be resolved by judicial reference, either party may seek from a court identified in
Section 11.9, any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial
reference. 
 11.11 Professional Fees. Borrower promises to pay Lender’s fees and expenses necessary to
finalize the loan documentation, including but not limited to reasonable attorneys fees, UCC searches, filing costs, and other miscellaneous expenses. In addition, Borrower promises to pay any and all reasonable attorneys’ and other
professionals’ fees and expenses (including fees and expenses of in-house counsel) incurred by Lender after the Closing Date in connection with or related to: (a) the Loan; (b) the administration, collection, or enforcement of the
Loan; (c) the amendment or modification of the Loan Documents; (d) any waiver, consent, release, or termination under the Loan Documents; (e) the protection, preservation, sale, lease, liquidation, or disposition of Collateral or the
exercise of remedies with respect to the Collateral; (f) any legal, litigation, administrative, arbitration, or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review thereof; and
(g) any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to Borrower, the Collateral, the Loan Documents, including representing Lender in any adversary proceeding
or contested matter commenced or continued by or on behalf of Borrower’s estate, and any appeal or review thereof. 
 11.12 Confidentiality. Lender acknowledges that certain items of Collateral and information provided to Lender by Borrower are confidential and proprietary information of Borrower, if and to the extent
such information either (x) is marked as confidential by Borrower at the time of disclosure, or (y) should reasonably be understood to be confidential (the “Confidential 

  
 24 

 
Information”). Accordingly, Lender agrees that any Confidential Information it may obtain in the course of acquiring, administering, or perfecting Lender’s security interest in the
Collateral shall not be disclosed to any other person or entity in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except that Lender may disclose any such information: (a) to its own directors,
officers, employees, accountants, counsel and other professional advisors and to its affiliates if Lender in its sole discretion determines that any such party should have access to such information in connection with such party’s
responsibilities in connection with the Loan or this Agreement and, provided that such recipient of such Confidential Information either (i) agrees to be bound by the confidentiality provisions of this paragraph or (ii) is otherwise
subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential Information; (b) if such information is generally available to the public through no fault of Lender; (c) if required or appropriate in
any report, statement or testimony submitted to any governmental authority having or claiming to have jurisdiction over Lender; (d) if required or appropriate in response to any summons or subpoena or in connection with any litigation, to the
extent permitted or deemed advisable by Lender’s counsel; (e) to comply with any legal requirement or law applicable to Lender; (f) to the extent reasonably necessary in connection with the exercise of any right or remedy under any
Loan Document, including Lender’s sale, lease, or other disposition of Collateral after default; (g) to any participant or assignee of Lender or any prospective participant or assignee; provided, that such participant or assignee or
prospective participant or assignee agrees in writing to be bound by this Section prior to disclosure; or (h) otherwise with the prior consent of Borrower; provided, that any disclosure made in violation of this Agreement shall not affect the
obligations of Borrower or any of its affiliates or any guarantor under this Agreement or the other Loan Documents. 
 11.13 Assignment of Rights. Borrower acknowledges and understands that Lender may sell and assign all or part of its interest hereunder and under the Note and Loan Documents to any person or entity (an
“Assignee”); provided, however, that Lender shall not sell or assign any rights pursuant to Section 8 of this Agreement, other than to an affiliate of either Lender (which assignment is permitted without consent of Borrower), without
the express written consent of Borrower, which consent may be withheld by Borrower in its sole discretion, and any such attempted assignment without such consent shall be void and of no effect. After such assignment the term “Lender” as
used in the Loan Documents shall mean and include such Assignee, and such Assignee shall be vested with all rights, powers and remedies of Lender hereunder with respect to the interest so assigned; but with respect to any such interest not so
transferred, Lender shall retain all rights, powers and remedies hereby given. No such assignment by Lender shall relieve Borrower of any of its obligations hereunder. Lender agrees that in the event of any transfer by it of the Note, it will
endorse thereon a notation as to the portion of the principal of the Note, which shall have been paid at the time of such transfer and as to the date to which interest shall have been last paid thereon. 

11.14 Revival of Secured Obligations. This Agreement and the Loan Documents shall remain in full force and effect and
continue to be effective if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any
significant part of Borrower’s assets, or if any payment or transfer of Collateral is recovered from Lender. The Loan Documents and the Secured Obligations and Collateral security shall continue to be effective, or shall be revived or
reinstated, as the case may be, if at any time payment and performance of the Secured Obligations or any transfer of Collateral to Lender, or any part thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or
returned by, or is recovered from, Lender or by any obligee of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment, performance, or

  
 25 

 
transfer of Collateral had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and
the Secured Obligations shall be deemed, without any further action or documentation, to have been revived and reinstated except to the extent of the full, final, and indefeasible payment to Lender in Cash. 

11.15 Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any
number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. 

11.16 No Third Party Beneficiaries. No provisions of the Loan Documents are intended, nor will be interpreted, to provide
or create any third-party beneficiary rights or any other rights of any kind in any person other than Lender and Borrower unless specifically provided otherwise herein, and, except as otherwise so provided, all provisions of the Loan Documents will
be personal and solely between Lender and the Borrower. 
 11.17 Publicity. Lender may use Borrower’s name
and logo, and include a brief description of the relationship between Borrower and Lender, in Lender’s marketing materials. 

(SIGNATURES TO FOLLOW) 

  
 26 

 IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Loan and
Security Agreement as of the day and year first above written. 
  

			
	BORROWER:
	
	REVANCE THERAPEUTICS, INC.
		
	Signature:	 	 /s/ David Styka

		
	Print Name:	 	 David Styka

		
	Title:	 	 Chief Financial Officer

 Accepted in Palo Alto, California: 

 

			
	LENDER:
	
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
		
	Signature:	 	 /s/ Scott Harvey

		
	Print Name:	 	 Scott Harvey

		
	Title:	 	 Chief Legal Officer

 Table of Exhibits and Schedules 

 

			
	Exhibit A:	  	 Advance Request
 Attachment to
Advance Request

		
	Exhibit B:	  	Term Note
		
	Exhibit C:	  	Name, Locations, and Other Information for Borrower
		
	Exhibit D:	  	Borrower’s Patents, Trademarks, Copyrights and Licenses
		
	Exhibit E:	  	Borrower’s Deposit Accounts and Investment Accounts
		
	Exhibit F:	  	Compliance Certificate
		
	Exhibit G:	  	Joinder Agreement
		
	Exhibit H:	  	ACH Debit Authorization Agreement
		
	Schedule 1	  	Subsidiaries
	Schedule 1A	  	Existing Permitted Indebtedness
	Schedule 1B	  	Existing Permitted Investments
	Schedule 1C	  	Existing Permitted Liens
	Schedule 5.3	  	Consents, Etc.
	Schedule 5.5	  	Actions Before Governmental Authorities
	Schedule 5.8	  	Tax Matters
	Schedule 5.9	  	Intellectual Property Claims
	Schedule 5.10	  	Intellectual Property
	Schedule 5.11	  	Borrower Products
	Schedule 5.14	  	Capitalization

 EXHIBIT A 
 ADVANCE REQUEST 
  

									
	To:	  	Lender:	  		 	Date:	  	            , 20    
					
		  	Hercules Technology Growth Capital, Inc.	  		 		  	
		  	400 Hamilton Avenue, Suite 310	  		 		  	
		  	Palo Alto, CA 94301	  		 		  	
		  	Facsimile: 650-473-9194	  		 		  	
		  	Attn:	  		 		  	

 Revance Therapeutics, Inc. (“Borrower”) hereby requests from Hercules Technology Growth Capital, Inc.
(“Lender”) an Advance in the amount of Twenty Two Million Dollars ($22,000,000) on             , 2011 (the “Advance Date”) pursuant to the Loan and Security Agreement
between Borrower and Lender (the “Agreement”). Capitalized words and other terms used but not otherwise defined herein are used with the same meanings as defined in the Agreement. 
 Please: 
  

							
	(a)	  	Issue a check payable to Borrower	  	  
	  	
				
		  	or	  		  	
				
	(b)	  	Wire Funds to Borrower’s account	  	  
	  	
				
		  	Bank:	  	  
	  	
		  	Address:	  	  
	  	
		  		  	  
	  	
		  	ABA Number:	  	  
	  	
		  	Account Number:	  	  
	  	
		  	Account Name:	  	  
	  	

 Borrower represents that the conditions precedent to the Advance set forth in the Agreement are satisfied
and shall be satisfied upon the making of the Advance, including but not limited to: (i) that no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing; (ii) that the
representations and warranties set forth in the Agreement and in the Warrant are and shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent
such representations and warranties expressly relate to an earlier date; (iii) that Borrower is in compliance with all the terms and provisions set forth in each Loan Document on its part to be observed or performed; and (iv) that as of
the Advance Date, no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default under the Loan Documents. Borrower understands and acknowledges that Lender has the right to
review the financial information supporting this representation and, based upon such review in its sole discretion, Lender may decline to fund the requested Advance. 
 Borrower hereby represents that Borrower’s corporate status and locations have not changed since the date of the Agreement or, if the Attachment to this Advance Request is completed, are as set forth
in the Attachment to this Advance Request. 

 Borrower agrees to notify Lender promptly before the funding of the Loan if any of the
matters which have been represented above shall not be true and correct on the Borrowing Date and if Lender has received no such notice before the Advance Date then the statements set forth above shall be deemed to have been made and shall be deemed
to be true and correct as of the Advance Date. 
 Executed as of
[            ], 2011. 
  

			
	BORROWER: REVANCE THERAPEUTICS, INC.
		
	SIGNATURE:	 	  

	TITLE:	 	  

	PRINT NAME:	 	  

 ATTACHMENT TO ADVANCE REQUEST 

Dated:                     

 Borrower hereby represents and warrants to Lender that Borrower’s current name and organizational status is as follows: 

 

			
	Name:	  	Revance Therapeutics, Inc.
		
	Type of organization:	  	Corporation
		
	State of organization:	  	Delaware
		
	Organization file number:	  	3074007

 Borrower hereby represents and warrants to Lender that the street addresses, cities, states and postal codes of its
current locations are as follows: 
  

	
	 7555 Gateway Boulevard

	 Newark, California 94560

 EXHIBIT B 
 SECURED TERM PROMISSORY NOTE 
  

			
	$22,000,000	  	Advance Date: September 20, 2011

 FOR VALUE RECEIVED, Revance Therapeutics, a Delaware corporation (the “Borrower”) hereby
promises to pay to the order of Hercules Technology Growth Capital, Inc., a Maryland corporation or the holder of this Promissory Note (the “Lender”) at 400 Hamilton Avenue, Suite 310, Palo Alto, CA 94301 or such other place of payment as
the holder of this Secured Term Promissory Note (this “Promissory Note”) may specify from time to time in writing, in lawful money of the United States of America, the principal amount of Twenty Two Million Dollars ($22,000,000) or such
other principal amount as Lender has advanced to Borrower, together with interest at a rate equal to the greater of (i) 9.85% or (ii) the sum of 9.85%, plus the prime rate as reported in The Wall Street Journal minus 3.25%; provided that,
if Borrower obtains at least $70,000,000 in cash proceeds from one or more Qualified Transaction that occurs on or before March 31, 2012, the interest rate under this Promissory Note shall be equal to the greater of (i) 8.50% or
(ii) the sum of 8.50%, plus the prime rate as reported in The Wall Street Journal minus 3.25%. 
 This Promissory Note is
the Note referred to in, and is executed and delivered in connection with, that certain Loan and Security Agreement dated September 20, 2011, by and between Borrower and Lender (as the same may from time to time be amended, modified or
supplemented in accordance with its terms, the “Loan Agreement”), and is entitled to the benefit and security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement
of all of the terms and conditions thereof. All payments shall be made in accordance with the Loan Agreement. All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein. An Event of
Default under the Loan Agreement shall constitute a default under this Promissory Note. 
 Borrower waives presentment and
demand for payment, notice of dishonor, protest and notice of protest under the UCC or any applicable law. Borrower agrees to make all payments under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or
defense. This Promissory Note has been negotiated and delivered to Lender and is payable in the State of California. This Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the State of California,
excluding any conflicts of law rules or principles that would cause the application of the laws of any other jurisdiction. 

[Signature to Follow] 

					
	BORROWER:	 	REVANCE THERAPEUTICS, INC.
			
		 	By:	 	
		 	Title:	 	

 {Signature Page to Note} 

 EXHIBIT C 
 NAME, LOCATIONS, AND OTHER INFORMATION FOR BORROWER 
 1. Borrower
represents and warrants to Lender that Borrower’s current name and organizational status as of the Closing Date is as follows: 
  

			
	Name:	  	ReVance Therapeutics, Inc.
		
	Type of organization:	  	Corporation
		
	State of organization:	  	Delaware
		
	Organization file number:	  	3074007

 2. Borrower represents and warrants to Lender that for five (5) years prior to the Closing Date,
Borrower did not do business under any other name or organization or form. 
 3. Borrower represents and warrants to Lender that
its chief executive office is located at 7555 Gateway Boulevard, Newark, California 94560. 
 4. Other locations of Collateral:
None 

 EXHIBIT D 
 BORROWER’S PATENTS, TRADEMARKS, COPYRIGHTS AND LICENSES 
 Patents: 

See Attached. 
 Trademarks: 

 

									
	 Trademark
	  	 Country
	  	 Class(es)
	  	Application	  	Status
					
	 COSMETIC ARTS
	  	United States of America	  	01 Int., 05 Int.	  	77980548	  	Registered
					
	 JANTYNG
	  	United States of America	  	03 Int., 05 Int.	  	77577292	  	Allowed
					
	 MOTISTE
	  	United States of America	  	03 Int., 05 Int.	  	77577293	  	Allowed
					
	 REVANCE
	  	European Community	  	03 Int., 05 Int.	  	EMR35	  	Registered
					
	 REVANCE
	  	United States of America	  	03 Int., 05 Int.	  	78726913	  	Registered
					
	 REVANCE
	  	United States of America	  	03 Int., 05 Int.	  	78978867	  	Registered
					
	 TRANSMTS
	  	United States of America	  	01 Int., 05 Int.	  	77514222	  	Registered
					
	 TRANSMTS
	  	United States of America	  	03 Int., 05 Int.	  	77514222	  	Allowed
					
	 XOTIKIS
	  	United States of America	  	03 Int., 05 Int.	  	77577295	  	Allowed

 Licenses: 
 The Company has entered into a License and Service Agreement with List Biological Laboratories, Inc. dated February 8, 2007, as amended on April 21, 2009. 

 EXHIBIT E 
 BORROWER’S DEPOSIT ACCOUNTS AND INVESTMENT ACCOUNTS 
  

			
	Type:	  	Checking Account
		
	Account Holder:	  	Revance Therapeutics, Inc.
		
	Type:	  	Money Market Account
		
	Account Holder:	  	Revance Therapeutics, Inc.
		
	Type:	  	Merchant Account
		
	Account Holder:	  	Revance Therapeutics, Inc.

 EXHIBIT F 
 COMPLIANCE CERTIFICATE 
 Hercules Technology Growth Capital, Inc. 

400 Hamilton Avenue, Suite 310 
 Palo Alto, CA
94301 
 Reference is made to that certain Loan and Security Agreement dated September 20, 2011 and all ancillary documents
entered into in connection with such Loan and Security Agreement all as may be amended from time to time, (hereinafter referred to collectively as the “Loan Agreement”) between Hercules Technology Growth Capital, Inc., as a Lender, and
Revance Therapeutics, Inc. (the “Company”) as Borrower. All capitalized terms not defined herein shall have the same meaning as defined in the Loan Agreement. 
 The undersigned is an Officer of the Company, knowledgeable of all Company financial matters, and is authorized to provide certification of information regarding the Company; hereby certifies that in
accordance with the terms and conditions of the Loan Agreement, the Company is in compliance for the period ending              of all covenants, conditions and terms and hereby reaffirms
that all representations and warranties contained therein are true and correct on and as of the date of this Compliance Certificate with the same effect as though made on and as of such date, except to the extent such representations and warranties
expressly relate to an earlier date, after giving effect in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations and warranties. Attached are the required documents supporting the above
certification. The undersigned further certifies that these are prepared in accordance with GAAP (except for the absence of footnotes with respect to unaudited financial statement and subject to normal year end adjustments) and are consistent from
one period to the next except as explained below. 
  

					
	REPORTING REQUIREMENT	 	REQUIRED	  	CHECK IF
ATTACHED
			
	Interim Financial Statements	 	Monthly within 30 days	  	
			
	A/R and A/P Agings	 	Monthly within 30 days	  	
			
	Interim Financial Statements	 	Quarterly within 30 days	  	
			
	Audited Financial Statements	 	FYE within 270 days	  	

  

			
	Very Truly Yours,
	
	REVANCE THERAPEUTICS, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Its:	 	  

 EXHIBIT G 
 FORM OF JOINDER AGREEMENT 
 This Joinder Agreement (the “Joinder
Agreement”) is made and dated as of [            ], 20[    ], and is entered into by and
between                            ., a
                     corporation (“Subsidiary”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (“Lender”).

 RECITALS 
 A. Subsidiary’s Affiliate, Revance Therapeutics, Inc. (“Company”) has entered into that certain Loan and Security Agreement dated September 20, 2011, with Lender, as such agreement may
be amended (the “Loan Agreement”), together with the other agreements executed and delivered in connection therewith; 

B. Subsidiary acknowledges and agrees that it will benefit both directly and indirectly from Company’s execution of the Loan
Agreement and the other agreements executed and delivered in connection therewith; 
 AGREEMENT 

NOW THEREFORE, Subsidiary and Lender agree as follows: 
  

	1.	The recitals set forth above are incorporated into and made part of this Joinder Agreement. Capitalized terms not defined herein shall have the meaning provided in the
Loan Agreement. 

  

	2.	By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of the Loan Agreement the same as if it were the Borrower (as defined in the
Loan Agreement) under the Loan Agreement, mutatis mutandis, provided however, that Lender shall have no duties, responsibilities or obligations to Subsidiary arising under or related to the Loan Agreement or the other agreements executed and
delivered in connection therewith. Rather, to the extent that Lender has any duties, responsibilities or obligations arising under or related to the Loan Agreement or the other agreements executed and delivered in connection therewith, those duties,
responsibilities or obligations shall flow only to Company and not to Subsidiary or any other person or entity. By way of example (and not an exclusive list): (a) Lender’s providing notice to Company in accordance with the Loan Agreement
or as otherwise agreed between Company and Lender shall be deemed provided to Subsidiary; (b) a Lender’s providing an Advance to Company shall be deemed an Advance to Subsidiary; and (c) Subsidiary shall have no right to request an
Advance or make any other demand on Lender. 

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

			
	 SUBSIDIARY:

	
	                           
                                     .
		
	 By:
	 	
	 Name:
	 	
	 Title:
	 	
		
	 Address:
	 	
		
	 Telephone:
	 	  

	 Facsimile:
	 	  

	
	 HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

	
	 Address:

	 400 Hamilton Ave., Suite 310

	 Palo Alto, CA 94301

	 Facsimile: 650-473-9194

	 Telephone: 650-289-3060

 [SIGNATURE PAGE TO JOINDER AGREEMENT] 

 EXHIBIT H 
 ACH DEBIT AUTHORIZATION AGREEMENT 
 Hercules Technology Growth Capital, Inc. 

400 Hamilton Avenue, Suite 310 
 Palo Alto, CA
94301 
 Re: Loan and Security Agreement dated September 20, 2011 between Revance Therapeutics, Inc. (“Borrower”)
and Hercules Technology Growth Capital, Inc. (“Company”) (the “Agreement”) 
 In connection with the above referenced
Agreement, the Borrower hereby authorizes the Company to initiate debit entries for the periodic payments due under the Agreement to the Borrower’s account indicated below. The Borrower authorizes the depository institution named below to debit
to such account. 
  

			
	 DEPOSITORY NAME
  
	  	BRANCH
	 CITY
  
	  	STATE AND ZIP CODE
	 TRANSIT/ABA NUMBER
  
	  	ACCOUNT NUMBER

 This authority will remain in full force and effect so long as any amounts are due under the Agreement. 

 

			
	  

	(Borrower)(Please Print)
		
	By:	 	  

		
	Date:	 	  

 Schedule 1A 

Existing Permitted Indebtedness 
 The Borrower and certain other purchasers entered into a Note and Warrant Purchase Agreement dated as of January 24, 2011, as amended pursuant to that certain Amendment dated as of February 10,
2011 and that certain Amendment dated as of March 28, 2011 and that certain Amendment dated as of May 31, 2011. 
 The Borrower has
entered into three separate Commercial Lease Agreements with Essex Capital Corporation dated August 10, 2010, November 10, 2010 and November 10, 2010. 
 The Borrower has entered into two separate Lease Agreements with Konica Minolta Business Solutions U.S.A., Inc. dated September 2, 2010 and March 9, 2011. 

 Schedule 1B 

Existing Permitted Investments 
 N/A 

 Schedule 1C 

Existing Permitted Liens 

The Borrower and certain other purchasers entered into a Note and Warrant Purchase Agreement dated as of January 24, 2011, as amended pursuant to
that certain Amendment dated as of February 10, 2011 and that certain Amendment dated as of March 28, 2011 and that certain Amendment dated as of May 31, 2011, pursuant to which the purchasers obtained a security interest in all
assets of Borrower. 
 The Borrower has entered into three separate Commercial Lease Agreements with Essex Capital Corporation dated
August 10, 2010, November 10, 2010 and November 10, 2010, pursuant to which the lender obtained a security interest in certain capital equipment of the Borrower. 
 The Borrower has entered into two separate Lease Agreements with Konica Minolta Business Solutions U.S.A., Inc. dated September 2, 2010 and March 9, 2011. 

The Medicis Agreements (see Schedule 5.3). 

 Schedule 1 

Subsidiaries 
 N/A

 Schedule 5.3 

Consents 
 The Borrower
and certain other purchasers entered into a Note and Warrant Purchase Agreement dated as of January 24, 2011, as amended on February 10, 2011, March 28, 2011 and May 31, 2011. 

The Borrower entered into a certain Option Agreement, dated as of December 11, 2007, by and between Medicis Pharmaceutical Corporation
(“Medicis”) and the Borrower (the “Option Agreement”), the Borrower has granted to Medicis an option (the “Medicis Option”) to: (i) acquire the Borrower through the merger of a newly-formed, wholly owned subsidiary
of Medicis with and into the Borrower in accordance with the Agreement and Plan of Merger, dated as of December 11, 2007, and the Delaware General Corporation Law (the “Merger Agreement”); or (ii) obtain an exclusive license for
the topical delivery of neurotoxin in North America in accordance with the License Agreement, dated as of December 11, 2007 (the “License Agreement”), pursuant to which the purchasers obtained a security interest in certain
intellectual property of the Borrower. The Option Agreement, Merger Agreement and License Agreement are referred to collectively as the Medicis Agreements. 
 The preferred stockholders of the Borrower entered a certain Action by Written Consent dated as of August 31, 2011. 

 Schedule 5.5 

Actions Before Governmental Authorities 
 N/A 

 Schedule 5.8 

Tax Matters 
 N/A

 Schedule 5.9 

Intellectual Property Claims 
 N/A 

 Schedule 5.10 

Intellectual Property 

Copyrights 
 N/A 

Trademarks 
 N/A 

Patents 
 N/A 

 Schedule 5.11 

Borrower Products 
 N/A

 Schedule 5.14 

Capitalization 
 The
Borrower is authorized to issue two classes of stock designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which the Borrower is authorized to issue is 69,598,825 shares, 42,000,000 shares of
which is Common Stock (the “Common Stock”) and 27,598,825 shares of which is Preferred Stock (the “Preferred Stock”). The Preferred Stock has a par value of $0.001 per share and the Common Stock has a par value of $0.001 per
share. 
 820,920 of the authorized shares of Preferred Stock are designated “Series A Preferred Stock,” 2,997,357 of the authorized
shares of Preferred Stock are designated as “Series B-1 Preferred Stock,” 2,022,653 of the authorized shares of Preferred Stock are designated as “Series B-2 Preferred Stock” (the Series B-1 Preferred Stock and Series B-2
Preferred Stock are referred to as the “Series B Preferred Stock”), 5,293,699 of the authorized shares of Preferred Stock are designated as “Series C-1 Preferred Stock,” 2,494,363 of the authorized shares of Preferred Stock are
designated as “Series C-2 Preferred Stock,” 2,228,260 of the authorized shares of Preferred Stock are designated as “Series C-3 Preferred Stock” (the Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series C-3
Preferred Stock are referred to as the “Series C Preferred Stock”), and 11,741,573 of the authorized shares of Preferred Stock are designated as “Series D Preferred Stock” (collectively with the Series A Preferred Stock, the
Series B Preferred Stock and the Series C Preferred Stock, the “Series Preferred”).EX-10.13

 Exhibit 10.13 
 AMENDMENT NO. 1 TO 
 LOAN AND SECURITY AGREEMENT 

THIS AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into this 8th day of
October, 2012, by and between REVANCE THERAPEUTICS, INC., a Delaware corporation (“Borrower”) and HERCULES TECHNOLOGY GROWTH CAPITAL, INC. (“Lender”). Capitalized terms used herein
without definition shall have the same meanings given them in the Loan Agreement (as defined below). 

RECITALS 
 A. Borrower and Lender have entered into that certain Loan and Security Agreement dated as of September 20, 2011 (as amended, restated, or otherwise modified, the “Loan
Agreement”), pursuant to which the Lender has extended and makes available to Borrower certain advances of money. 

B. Borrower desires that Lender amend the Loan Agreement upon the terms and conditions more fully set forth herein. Subject to the
representations and warranties of Borrower herein and upon the terms and conditions set forth in this Amendment, Lender is willing to so amend the Loan Agreement. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the foregoing Recitals and
intending to be legally bound, the parties hereto agree as follows: 
 1. AMENDMENTS TO
LOAN AGREEMENT. 
 1.1 Section 1.1 (Definitions and Rules of
Construction). The following definitions are hereby: (a) to the extent already defined in Section 1.1 of the Loan Agreement, amended in their entirety to read as follows, and (b) to the extent not already defined in that Section,
added to Section 1.1 of the Loan Agreement in alphabetical order as follows: 
 ““Permitted Indebtedness”
means: (i) Indebtedness of Borrower in favor of Lender arising under this Agreement or any other Loan Document; (ii) Indebtedness existing on the Closing Date which is disclosed in Schedule 1A; (iii) Indebtedness of up to $5,000,000
outstanding at any time secured by a lien described in clause (vii) of the defined term “Permitted Liens,” provided such Indebtedness does not exceed the lesser of the cost or fair market value (determined as of the date on which such
Equipment is financed) of the Equipment financed with such Indebtedness; (iv) Indebtedness to trade creditors incurred in the ordinary course of business, including Indebtedness incurred in the ordinary course of business with corporate credit
cards; (v) Indebtedness that also constitutes a Permitted Investment; (vi) Subordinated Indebtedness; (vii) reimbursement obligations in connection with letters of credit that are secured by cash or cash equivalents and issued on
behalf of the Borrower or a Subsidiary thereof in an amount not to exceed $200,000 at any time outstanding, (viii) Indebtedness pursuant to the Medicis Settlement Agreement; (ix) other Indebtedness in an amount not to exceed $100,000 at
any time outstanding, and (x) extensions, refinancings and renewals of any of items (i) – (vii) of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified to impose materially more
burdensome terms upon Borrower or its Subsidiary, as the case may be.” 

  
 1 

 ““Permitted Transfers” means (i) sales of Inventory in the normal course
of business, (ii) non-exclusive and exclusive licenses and similar arrangements for the use of Intellectual Property on commercially reasonable terms that could not result in a legal transfer of title of the licensed property, or
(iii) dispositions of worn-out, obsolete or surplus Equipment at fair market value in the ordinary course of business, (iv) dispositions expressly permitted under Section 7.7, 7.8 or 7.9, (v) dispositions arising from the
abandonment of fixtures and other similar tenant improvements in connection with office relocations in the ordinary course of business, (vi) cash payments due to Medicis pursuant to the Medicis Settlement Agreement and permitted by the Medicis
Subordination Agreement, (vii) other Transfers of assets having a fair market value of not more than $250,000 in the aggregate in any fiscal year and (viii) any Permitted Injectable Rights Transfers.” 

““Medicis” means Medicis Pharmaceutical Corporation, a Delaware corporation.” 

““Medicis Settlement Agreement” means that certain Settlement and Termination Agreement by and between Borrower and
Medicis dated as of October 8, 2012.” 
 ““Medicis Subordination Agreement” means that certain
Subordination Agreement by and among Medicis, Borrower and Lender made as of October 8, 2012.” 
 1.2
Section 7.14 (Payments to Officers). A new Section 7.14 is added to the Loan Agreement as follows: 

““7.14 Payments to Officers. Borrower shall not pay bonus payments to employees of Borrower who are stockholders of
Borrower if doing so would result in an Acceleration Transaction pursuant to the Medecis Settlement Agreement.” 
 2.
WAIVER AND CONSENT. Lender hereby (a) consents to Borrower entering into the Medicis Settlement Agreement and Borrower’s performance of its obligations thereunder (including the termination
of the Medicis Agreements (as set forth on Schedule 5.3 to the Loan Agreement) and that certain License Agreement by and between Borrower and Medicis dated July 27, 2009), subject to the terms of the Medicis Subordination Agreement; and
(b) waives any Event of Default that exists as of the date hereof which arises from the events and circumstances related to the Medicis Settlement Agreement and the termination of the contracts with Medicis as provided therein, and including
without limitation the litigation matter between Borrower and Medicis, which is being resolved by the Medicis Settlement Agreement.  
 3. LIMITATION. The waiver, consent and amendments set forth in this Amendment shall be limited precisely as written and shall not be deemed (a) to be a
forbearance, waiver or modification of any other term or condition of the Loan Agreement or of any other instrument or agreement referred to therein or to prejudice any right or remedy which Lender may now have or may have in the future under or in
connection with the Loan Agreement or any instrument or agreement referred to therein; (b) to be a consent to any future amendment or modification, forbearance or waiver to any instrument or agreement the execution and delivery of which is
consented to hereby, or to any waiver of any of the provisions thereof; or (c) to limit or impair Lender’s right to demand strict performance of all terms and covenants as of any date. Except as expressly amended hereby, the Loan Agreement
shall continue in full force and effect. 
 4. REPRESENTATIONS AND WARRANTIES.
To induce Lender to enter into this Amendment, Borrower hereby represents and warrants to Lender as follows: 

  
 2 

 4.1 Immediately after giving effect to this Amendment (a) the representations
and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and
correct as of such date), and (b) no Event of Default has occurred and is continuing; 
 4.2 Borrower has the
corporate power and authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment; 
 4.3 A true, accurate and complete copy of Borrower’s amended and restated certificate of incorporation filed on or about the date hereof is attached hereto as Exhibit B and none of
Borrower’s other organizational documents been amended, supplemented or restated and each are and continue to be in full force and effect; 
 4.4 The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly authorized;

 4.5 The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under
the Loan Agreement, as amended by this Amendment, do not and will not contravene (a) any material Requirement of Law, (b) any material agreement binding on Borrower, (c) any order, judgment or decree of any court or other governmental
or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower; 

4.6 The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision
thereof, binding on either Borrower, except as already has been obtained or made or except for any filing, recording, or registration required by the Securities Exchange Act of 1934; and 

4.7 This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against
Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting
creditors’ rights. 
 5. EFFECTIVENESS. This Amendment shall become effective upon the
satisfaction of all the following conditions precedent: 
 5.1 Amendment. Borrower shall have duly executed and delivered
to Lender (a) this Amendment; and (b) the Subordination Agreement of Medicis Pharmaceutical Corporation in the form attached hereto as Exhibit A; 
 5.2 Issuance of Additional Notes. On or after October 5, 2012, Borrower shall have received proceeds of not less than $7,000,000 in respect of notes issued by it pursuant to that certain Note
and Warrant Purchase Agreement dated as of January 24, 2011, as amended, or the sale and issuance of debt or equity securities of Borrower (provided that if such proceeds 

  
 3 

 
are received through the sale of debt securities, the holders of such debt securities shall be subject to a subordination agreement in form and substance satisfactory to Lender); and 

5.3 Payment of Lender Expenses. Borrower shall have paid all Lender Expenses (including all reasonable attorneys’ fees and
reasonable expenses) incurred through the date of this Amendment. 
 6. COUNTERPARTS. This
Amendment may be signed in any number of counterparts, and by different parties hereto in separate counterparts, with the same effect as if the signatures to each such counterpart were upon a single instrument. All counterparts shall be deemed an
original of this Amendment. 
 7. INTEGRATION. This Amendment and any documents executed in
connection herewith or pursuant hereto contain the entire agreement between the parties with respect to the subject matter hereof and supersede all prior agreements, understandings, offers and negotiations, oral or written, with respect thereto and
no extrinsic evidence whatsoever may be introduced in any judicial or arbitration proceeding, if any, involving this Amendment; except that any financing statements or other agreements or instruments filed by Lender with respect to Borrower shall
remain in full force and effect. 
 8. GOVERNING LAW; VENUE. THIS AMENDMENT
SHALL BE GOVERNED BY AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA. Borrower and Lender each submit to the exclusive jurisdiction of the State and Federal courts in Santa Clara County, California.

 [signature page follows] 

  
 4 

							
	BORROWER:	 		 	 REVANCE THERAPEUTICS, INC.,
 a Delaware corporation

				
		 		 	Signature:	 	 /s/ L. Daniel Browne

		 		 	Name:	 	 L. Daniel Browne

		 		 	Title:	 	 President and CEO

			
	LENDER:	 		 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
				
		 		 	Signature:	 	 /s/ K. Nicholas Martlisch

		 		 	Name:	 	 K. Nicholas Martlisch

		 		 	Title:	 	 Associate General Counsel

  
 5 

 EXHIBIT A 

SUBORDINATION AGREEMENT 

 SUBORDINATION AGREEMENT 

This Subordination Agreement is made as of October 8, 2012 by and among MEDICIS PHARMACEUTICAL CORPORATION
(“Creditor”), REVANCE THERAPEUTICS, INC. (“Borrower”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC. (the “Lender”). 
 Recitals 
 A. Borrower has requested and/or obtained certain loans or other
credit accommodations from Lender which are or may be from time to time secured by assets and property of Borrower pursuant to the terms of that certain Loan and Security Agreement dated September 20, 2011 by and between Borrower and Lender
(the “Loan Agreement”). 
 B. Creditor has agreed to accept a series of payments from Borrower pursuant to that
certain Settlement and Termination Agreement between Creditor and Borrower dated as of October 8, 2012 (the “Settlement Agreement”). 
 C. Creditor is willing to subordinate: (i) all of Borrower’s payment obligations to such Creditor, whether presently existing or arising in the future under the Settlement Agreement (the
“Subordinated Debt”) to all of Borrower’s indebtedness and obligations to Lender; and (ii) all of Creditor’s security interests, if any, in Borrower’s property, to all of Lender’s security interests in the
Borrower’s property. 
 NOW, THEREFORE, THE PARTIES AGREE AS FOLLOWS: 

1. Creditor does not claim, will not demand, and has not been granted, any security interest in any assets of Borrower to secure the
obligations of Borrower under the Settlement Agreement. In the event that Creditor does obtain a security interest in, or lien on, any of Borrower’s assets, in violation of this Subordination Agreement or otherwise, Creditor subordinates to
Lender any security interest or lien that Creditor may have in any property of Borrower. Notwithstanding the respective dates of attachment or perfection of the security interest of Creditor and the security interest of Lender, the security interest
of Lender in the Collateral, as defined in the Loan Agreement, shall at all times be prior to the security interest of Creditor. Capitalized terms not otherwise defined herein shall have the same meaning as in the Loan Agreement. 

2. All Subordinated Debt is subordinated in right of payment to all obligations of Borrower to Lender now existing or hereafter arising,
together with all costs of collecting such obligations (including attorneys’ fees), including, without limitation, all interest accruing after the commencement by or against Borrower of any Bankruptcy, reorganization or similar proceeding, and
all obligations under the Loan Agreement (the “Senior Debt”). Notwithstanding the foregoing, Borrower may make, and Creditor may receive, payments that become due to Creditor after the date hereof in accordance with the Settlement
Agreement so long as no Event of Default under the Loan Agreement has occurred and then exists, or would result from any such payments. 
 3. Creditor will not exercise any remedy with respect to, or realize upon, the Collateral for so long as any portion of the Senior Debt remains outstanding, provided (a) Creditor may bring an action
against Borrower to compel performance under the Settlement Agreement and/or for the payment of damages for breach thereof, and obtain a judgment in respect thereof, and (b) Creditor may convert any part of Subordinated Debt into equity
securities of Borrower in accordance with the terms of the Settlement Agreement. 

 4. Creditor shall promptly deliver to Lender in the form received (except for endorsement or
assignment by such Creditor where required by Lender) for application to the Senior Debt any payment, distribution, security or proceeds received by Creditor with respect to the Subordinated Debt other than in accordance with this Agreement.

 5. In the event of Borrower’s insolvency, reorganization or any case or proceeding under any Bankruptcy or insolvency
law or laws relating to the relief of debtors, these provisions shall remain in full force and effect, and Lender’s claims against Borrower and the estate of Borrower shall be paid in full before any payment is made to Creditor. 

6. For so long as any of the Senior Debt remains unpaid, Creditor irrevocably appoints Lender as Creditor’s attorney-in-fact, and
grants to Lender a power of attorney with full power of substitution, in the name of Creditor or in the name of Lender, for the use and benefit of Lender, without notice to Creditor, to perform at Lender’s option the following acts in any
Bankruptcy, insolvency or similar proceeding involving Borrower: 
 (i) To file the appropriate claim or claims in respect of
the Subordinated Debt on behalf of Creditor if Creditor does not do so prior to 30 days before the expiration of the time to file claims in such proceeding and if Lender elects, in its sole discretion, to file such claim or claims; and 

(ii) To accept or reject any plan of reorganization or arrangement on behalf of Creditor and to otherwise vote Creditor’s claims in
respect of any Subordinated Debt in any manner that Lender deems appropriate for the enforcement of its rights hereunder. 
 7.
Creditor shall immediately affix a legend to the instruments, if any, evidencing the Subordinated Debt stating that the instruments are subject to the terms of this Agreement. No amendment of the Settlement Agreement or other documents relating to
the Subordinated Debt shall directly or indirectly modify the provisions of this Agreement in any manner which might terminate or impair the subordination of the Subordinated Debt or the subordination of any security interest or lien that such
Creditor may have in any property of Borrower. By way of example, such documents shall not be amended to accelerate the timing of the payments due under the Settlement Agreement. 

8. This Agreement shall remain effective for so long as the Lender has any obligation to make credit extensions to Borrower or Borrower
owes any amounts to Lender under the Loan Agreement or otherwise. If, at any time after payment in full of the Senior Debt any payments of the Senior Debt must be disgorged by Lender for any reason (including, without limitation, the Bankruptcy of
Borrower), this Agreement and the relative rights and priorities set forth herein shall be reinstated as to all such disgorged payments as though such payments had not been made and Creditor shall immediately pay over to Lender all payments received
with respect to the Subordinated Debt to the extent that such payments would have been prohibited hereunder. At any time and from time to time, without notice to Creditor, Lender may take such actions with respect to the Senior Debt as Lender, in
its sole discretion, may deem appropriate, including, without limitation, terminating advances to Borrower, increasing the principal amount, extending the time of payment, increasing applicable interest rates, renewing, compromising or otherwise
amending the terms of any documents affecting the Senior Debt and any collateral securing the Senior Debt, and enforcing or failing to enforce any rights against Borrower or any other person. No such action or inaction shall impair or otherwise
affect Lender’s rights hereunder. 
 9. This Agreement shall bind any successors or assignees of Creditor and shall benefit
any successors or assigns of Lender. This Agreement is solely for the benefit of Creditor and Lender and not for the benefit of Borrower or any other party. Creditor further agrees that if Borrower is in the process of refinancing a portion of the
Senior Debt with a new lender, and if Lender makes a request of Creditor, 

 
Creditor shall agree to enter into a new subordination agreement with the new lender on substantially the terms and conditions of this Agreement. 

10. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall
constitute one instrument. 
 11. This Agreement shall be governed by, and construed in accordance with, the internal laws of
the State of California, without regard to principles of conflicts of law. Jurisdiction shall lie in the State of California. THE UNDERSIGNED ACKNOWLEDGE THAT THE RIGHT TO TRIAL BY JURY IS A CONSTITUTIONAL ONE, BUT THAT IT MAY BE WAIVED UNDER
CERTAIN CIRCUMSTANCES. TO THE EXTENT PERMITTED BY LAW, EACH PARTY, AFTER CONSULTING (OR HAVING HAD THE OPPORTUNITY TO CONSULT) WITH COUNSEL OF ITS, HIS OR HER CHOICE, KNOWINGLY AND VOLUNTARILY, AND FOR THE MUTUAL BENEFIT OF ALL PARTIES, WAIVES ANY
RIGHT TO TRIAL BY JURY IN THE EVENT OF LITIGATION ARISING OUT OF OR RELATED TO THIS AGREEMENT OR ANY OTHER DOCUMENT, INSTRUMENT OR AGREEMENT BETWEEN THE UNDERSIGNED PARTIES. If the jury waiver set forth in this Section is not enforceable, then any
dispute, controversy or claim arising out of or relating to this Agreement or any of the transactions contemplated herein shall be resolved by judicial reference pursuant to Code of Civil Procedure Section 638 et seq before a mutually
acceptable referee or, if none is selected, then a referee chosen by the Presiding Judge of the California Superior Court for Santa Clara County, provided this provision shall not restrict any party from seeking to enforce any prejudgment remedies.

 12. This Agreement represents the entire agreement with respect to the subject matter hereof, and supersedes all prior
negotiations, agreements and commitments. Creditor is not relying on any representations by Lender or Borrower in entering into this Agreement, and Creditor has kept and will continue to keep itself fully apprised of the financial and other
condition of Borrower. This Agreement may be amended only by written instrument signed by Creditor and Lender. 
 13. In the
event of any legal action to enforce the rights of a party under this Agreement, the party prevailing in such action shall be entitled, in addition to such other relief as may be granted, all reasonable costs and expenses, including reasonable
attorneys’ fees, incurred in such action. 
 [SIGNATURE PAGE FOLLOWS]

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first above
written. 
  

			
	“Lender”
	
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
		
	By:	 	 /s/ K. Nicholas Martlisch

		
	Title:	 	 Assistant General Counsel

	
	“Borrower”
	
	REVANCE THERAPEUTICS, INC.
		
	By:	 	 /s/ L. Daniel Browne

		
	Title:	 	 President and Chief Executive Officer

	
	“Creditor”
	
	MEDICIS PHARMACEUTICAL CORPORATION
		
	By:	 	 /s/ Richard D. Peterson

		
	Title:	 	 Chief Financial Officer

 EXHIBIT B 

BORROWER’S CERTIFICATE OF INCORPORATION 

 CERTIFICATE OF AMENDMENT OF THE 

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION 
 OF 
 REVANCE THERAPEUTICS, INC. 

REVANCE THERAPEUTICS, INC., a corporation organized and existing under
and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 
 FIRST: The name of the corporation is Revance Therapeutics, Inc. (the “Corporation”). 

SECOND: The original name of this company is Essentia Biosystems, Inc. and the date of filing the original
Certificate of Incorporation of this company with the Secretary of State of the State of Delaware was August 10, 1999. 

THIRD: The Board of Directors of the Corporation, acting in accordance with the provisions of Sections 141 and
242 of the DGCL, adopted resolutions amending its Amended and Restated Certificate of Incorporation as follows: 
 1.
Article IV Section D(2)(e)(i) of the Amended and Restated Certificate of Incorporation of the Corporation is hereby amended and restated to read as follows: 
 “(i) Any amendment, alteration, or repeal of any provision of the Certificate of Incorporation of the Company, that alters or changes the voting or other powers, preferences, or other special
rights, privileges or restrictions of the Series C-3 Preferred Stock so as to affect them adversely in a manner different than other classes or series of stock (provided that any such amendment, alteration or repeal that alters or changes the voting
or other powers, preferences, or other special rights, privileges or restrictions of all of the Series C Preferred Stock, or all of the Series Preferred, in a proportional manner, shall not be deemed to affect the Series C-3 Preferred Stock
adversely in a manner different than the other series of such class); or” 
 2. Article IV Section D(2)(g)(iii) of
the Amended and Restated Certificate of Incorporation of the Corporation is hereby amended and restated to read as follows: 

“(iii) Reserved.” 
 3. Article IV Section D(5)(l)(i) of the Amended and Restated Certificate of Incorporation of the Corporation is hereby amended and restated to read as follows: 

“(i) Each share of Series Preferred shall automatically be converted into shares of Common Stock, based on the then-effective
Series Preferred Conversion Price, (A) at any time upon the affirmative election of the holders of at least a majority of the outstanding shares of the Series Preferred, (B) immediately upon the

 
closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of Common Stock for the
account of the Company (a “Public Offering”), upon the affirmative election of the holders of at least a majority of the outstanding shares of the Series Preferred, or (C) immediately upon the closing of a Public
Offering in which the per share price is at least $13.35 (as adjusted for stock splits, dividends, recapitalizations and the like after the filing date hereof), and the gross cash proceeds to the Company (before underwriting discounts, commissions
and fees) are at least $50,000,000 (in each case, a “Qualified Public Offering”).” 

FOURTH: Thereafter, pursuant to a resolution by the Board of Directors, this Certificate of Amendment of Amended
and Restated Certificate of Incorporation was submitted to the stockholders of the Company for their approval in accordance with the provisions of Section 228 and 242 of the DGCL. Accordingly, said proposed amendment has been adopted in
accordance with Section 242 of the DGCL. 
 [SIGNATURE PAGE FOLLOWS]

 IN WITNESS WHEREOF,
REVANCE THERAPEUTICS, INC. has caused this Certificate of Amendment of the Amended and Restated Certificate of Incorporation to be signed by its President this 8th day of November,
2012. 
  

	
	REVANCE THERAPEUTICS, INC.
	
	 /s/ L. Daniel Browne

	L. Daniel Browne
	President

 AMENDED AND RESTATED 

CERTIFICATE OF INCORPORATION 
 OF 
 REVANCE THERAPEUTICS, INC. 

L. DANIEL BROWNE hereby certifies that: 

ONE: The original name of this company is Essentia Biosystems, Inc. and the date of filing the original Certificate of
Incorporation of this company with the Secretary of State of the State of Delaware was August 10, 1999. 
 TWO: He
is the duly elected and acting President of REVANCE THERAPEUTICS, INC., a Delaware corporation. 
 THREE: The Certificate of Incorporation of this company is hereby amended and restated to read as follows: 
 I. 
 The name of this company is REVANCE
THERAPEUTICS, INC. (the “Company” or the “Corporation”). 
 II. 
 The address of the registered office of the Corporation in the State
of Delaware is 9 E. Lookerman Street, City of Dover, County of Kent, and the name of the registered agent of the Corporation in the State of Delaware at such address is National Registered Agents, Inc. 

III. 

The purpose of the Company is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General
Corporation Law (“DGCL”). 
 IV. 

A. The Company is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and
“Preferred Stock.” The total number of shares which the Company is authorized to issue is 69,598,825 shares, 42,000,000 shares of which shall be Common Stock (the “Common Stock”) and 27,598,825 shares of which shall
be Preferred Stock (the “Preferred Stock”). The Preferred Stock shall have a par value of $0.001 per share and the Common Stock shall have a par value of $0.001 per share. 

B. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares of Common
Stock then outstanding) by the affirmative vote of the holders of a majority of the stock of the Company (voting together on an as-if-converted basis). 

 C. 820,920 of the authorized shares of Preferred Stock are hereby designated
“Series A Preferred Stock,” 2,997,357 of the authorized shares of Preferred Stock are hereby designated as “Series B-1 Preferred Stock,”
2,022,653 of the authorized shares of Preferred Stock are hereby designated as “Series B-2 Preferred Stock” (the Series B-1 Preferred Stock and Series B-2 Preferred Stock are referred to as the “Series B Preferred
Stock”), 5,293,699 of the authorized shares of Preferred Stock are hereby designated as “Series C-1 Preferred Stock,” 2,494,363 of the authorized shares of Preferred Stock are hereby
designated as “Series C-2 Preferred Stock,” 2,228,260 of the authorized shares of Preferred Stock are hereby designated as “Series C-3 Preferred Stock” (the Series C-1 Preferred Stock,
Series C-2 Preferred Stock and Series C-3 Preferred Stock are generally referred to as the “Series C Preferred Stock”), and 11,741,573 of the authorized shares of Preferred Stock are hereby designated as
“Series D Preferred Stock” (collectively with the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock, the “Series Preferred”). 

D. The rights, preferences, privileges, restrictions and other matters relating to the Series Preferred are as follows:

  

	 	1.	DIVIDEND RIGHTS. 

 (a) Holders of Series D Preferred Stock, in preference to the holders of Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock and Common Stock, shall be entitled to receive,
when and as declared by the Board of Directors (the “Board”), but only out of funds that are legally available therefor, non-cumulative cash dividends at the rate of eight percent (8%) of the applicable Original Issue
Price (as defined below) per annum on each outstanding share of Series D Preferred Stock (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares after the filing date hereof). Holders of
Series C Preferred Stock, in preference to the holders of Series B Preferred Stock, Series A Preferred Stock and Common Stock, shall be entitled to receive, when and as declared by the Board, but only out of funds that are legally available
therefor, non-cumulative cash dividends at the rate of eight percent (8%) of the applicable Original Issue Price (as defined below) per annum on each outstanding share of Series C Preferred (as adjusted for any stock dividends, combinations,
splits, recapitalizations and the like with respect to such shares after the filing date hereof). Holders of Series B Preferred and Series A Preferred, in preference to the holders of Common Stock, shall be entitled to receive, when and as declared
by the Board, but only out of funds that are legally available therefor, cash dividends at the rate of eight percent (8%) of the applicable Original Issue Price (as defined below) per annum on each outstanding share of Series B Preferred Stock
and Series A Preferred Stock (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares after the filing date hereof). Such dividends shall be payable only when, as and if declared by the
Board and shall be non-cumulative. 
 (b) The “Original Issue Price” of the Series A Preferred Stock shall be
$2.20 (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares after the filing date hereof). The Original Issue Price of the Series B-1 Preferred Stock shall be $2.36 (as adjusted for
any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares after the filing date hereof). The 

 
Original Issue Price of the Series B-2 Preferred Stock shall be $3.09 (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares after
the filing date hereof). The Original Issue Price of the Series C-1 Preferred Stock shall be $4.25 (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares after the filing date hereof).
The Original Issue Price of the Series C-2 Preferred Stock shall be $5.50 (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares after the filing date hereof). The Original Issue Price
of the Series C-3 Preferred Stock shall be $9.20 (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares after the filing date hereof). The Original Issue Price of the Series D Preferred
Stock shall be $4.45 (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares after the filing date hereof). 
 (c) So long as any shares of Series Preferred are outstanding, the Company shall not pay or declare any dividend, whether in cash or property, or make any other distribution on the Common Stock, or
purchase, redeem or otherwise acquire for value any shares of Common Stock until all dividends as set forth in Section 1(a) above on the Series Preferred shall have been paid or declared and set apart, except for: 

(i) acquisitions of Common Stock by the Company pursuant to agreements which permit the Company to repurchase such shares at cost
(or the lesser of cost or fair market value) upon termination of services to the Company; or 
 (ii) acquisitions of
Common Stock in the exercise of the Company’s right of first refusal to repurchase such shares. 
 (d) In the event
dividends are paid on any share of Common Stock, the Company shall pay concurrently to the holders of Series Preferred an additional dividend on all outstanding shares of Series Preferred in a per share amount equal (on an as-if-converted to Common
Stock basis) to the amount paid or set aside for each share of Common Stock. 
 (e) Dividends payable in Common Stock
shall be paid equally among the holders of Common Stock and the Series Preferred (on an as-converted to Common Stock basis). 

(f) The provisions of Sections 1(c) and 1(d) shall not apply to any repurchase of any outstanding securities of the Company that
is approved by the Board and a majority of the holders of the Series Preferred. 
 (g) The holders of the Series
Preferred expressly waive their rights, if any, as described in California Code Sections 502, 503 and 506 as they relate to repurchases of shares of Common Stock upon termination of employment or service as a consultant or director. 

	 	2.	VOTING RIGHTS. 

 (a) General Rights. Each holder of shares of the Series Preferred shall be entitled to the number of votes equal to the number of shares of Common Stock into which such shares of Series Preferred
could be converted (pursuant to Section 5 hereof) immediately after the close of business on the record date fixed for such meeting or the effective date of such written consent and shall have voting rights and powers equal to the voting rights
and powers of the Common Stock and shall be entitled to notice of any stockholders’ meeting in accordance with the bylaws of the Company. Except as otherwise provided herein or as required by law, the Series Preferred shall vote together with
the Common Stock at any annual or special meeting of the stockholders and not as a separate class, and may act by written consent in the same manner as the Common Stock. 
 (b) Separate Vote of Series Preferred. For so long as at least 3,500,000 shares of Series Preferred (subject to adjustment for any stock split, reverse stock split or other similar event
affecting the Series Preferred after the filing date hereof) remain outstanding, in addition to any other vote or consent required herein or by law, the vote or written consent of the holders of at least a majority of the outstanding Series
Preferred shall be necessary for effecting or validating the following actions: 
 (i) Any amendment, alteration, or
repeal of any provision of the Certificate of Incorporation of the Company; 
 (ii) Any increase or decrease in the
authorized number of shares of Preferred Stock; 
 (iii) Any authorization or any designation, whether by
reclassification or otherwise, or issuance of any new class or series of stock or any other securities convertible into equity securities of the Company ranking on a parity with or senior to the Series D Preferred in right of redemption, liquidation
preference, voting or dividend rights; 
 (iv) Any redemption or repurchase with respect to Common Stock or Preferred
Stock other than dividends required pursuant to Section 1 hereof (except for (x) acquisitions of Common Stock by the Company from directors, employees and consultants not to exceed $100,000 in any twelve month period, (y) acquisitions
of capital stock pursuant to agreements with employees, officers, directors, consultants or other person providing services to the Company upon the termination of such services), or (z) acquisitions of Series D Preferred Stock following an
Asset Transfer or Acquisition (each as defined in Section 4(c)); 
 (v) Any payment or declaration of dividends
with respect to Common Stock other than dividends required pursuant to Section 1 hereof and except for acquisitions of Common Stock by the Company permitted by Section 1(c) hereof; 

(vi) Any agreement by the Company or its stockholders that would effect or result in an Asset Transfer or Acquisition (each as
defined in Section 4(c)); 
 (vii) Any voluntary dissolution or liquidation of the Company; 

 (viii) Any sale by the Company of securities of a subsidiary of the Company to a
third party; 
 (ix) Any increase or decrease in the authorized number of members of the Company’s Board; or

 (x) Any incurrence of indebtedness for borrowed money in excess of $3,000,000 in the aggregate, other than any
refinancing of existing indebtedness for borrowed money for an amount not in excess of the amount outstanding as of the Original Issue Date. 
 (c) Separate Vote of Series B Preferred. For so long as at least 600,000 shares of Series B Preferred Stock (subject to adjustment for any stock split, reverse stock split or other similar
event affecting the Series B Preferred Stock after the filing date hereof) remain outstanding, in addition to any other vote or consent required herein or by law, the vote or written consent of the holders of at least a majority of the outstanding
Series B Preferred Stock shall be necessary for effecting or validating the following actions: 
 (i) Any amendment,
alteration, or repeal of any provision of the Certificate of Incorporation of the Company, that alters or changes the voting or other powers, preferences, or other special rights, privileges or restrictions of the Series B Preferred Stock so as to
affect them adversely in a manner different than other classes of stock; or 
 (ii) Any increase or decrease in the
authorized number of shares of Series B Preferred Stock. 
 (d) Separate Vote of Series C Preferred. For so long
as at least 4,000,000 shares of Series C Preferred Stock (subject to adjustment for any stock split, reverse stock split or other similar event affecting the Series C Preferred Stock after the filing date hereof) remain outstanding, in addition to
any other vote or consent required herein or by law, the vote or written consent of the holders of at least a majority of the outstanding Series C Preferred Stock shall be necessary for effecting or validating the following actions: 

(i) Any amendment, alteration, or repeal of any provision of the Certificate of Incorporation of the Company, that alters or
changes the voting or other powers, preferences, or other special rights, privileges or restrictions of the Series C Preferred Stock so as to affect them adversely in a manner different than other classes or series of stock; or 

(ii) Any increase or decrease in the authorized number of shares of Series C Preferred Stock. 

(e) Separate Vote of Series C-3 Preferred. For so long as at least 1,086,957 shares of Series C-3 Preferred Stock (subject
to adjustment for any stock split, reverse stock split or other similar event affecting the Series C-3 Preferred Stock after the filing date hereof) remain outstanding, in addition to any other vote or consent required herein or by law, the vote or
written consent of the holders of at least a majority of the outstanding Series C-3 Preferred Stock shall be necessary for effecting or validating the following actions: 

 (i) Any amendment, alteration, or repeal of any provision of the Certificate of
Incorporation of the Company, that alters or changes the voting or other powers, preferences, or other special rights, privileges or restrictions of the Series C-3 Preferred Stock so as to affect them adversely in a manner different than other
classes or series of stock; or 
 (ii) Any increase or decrease in the authorized number of shares of Series C-3
Preferred Stock. 
 (f) Separate Vote of Series D Preferred. For so long as at least 3,000,000 shares of Series D
Preferred Stock (subject to adjustment for any stock split, reverse stock split or other similar event affecting the Series D Preferred Stock after the filing date hereof) remain outstanding, in addition to any other vote or consent required herein
or by law, the vote or written consent of the holders of at least a majority of the outstanding Series D Preferred Stock shall be necessary for effecting or validating the following actions: 

(i) Any amendment, alteration, or repeal of any provision of the Certificate of Incorporation of the Company, that alters or
changes the voting or other powers, preferences, or other special rights, privileges or restrictions of the Series D Preferred Stock so as to affect them adversely in a manner different than other classes or series of stock; 

(ii) Any increase or decrease in the authorized number of shares of Series D Preferred Stock or any other series of the Series
Preferred; or 
 (iii) Any authorization or issuance of any security having voting, liquidation, participation,
redemption or dividend rights senior to or pari passu with the Series D Preferred. 
 (g) Election of Board of
Directors. 
 (i) For so long as at least 3,000,000 shares of Series D Preferred Stock remains outstanding (subject
to adjustment for any stock split, reverse stock split or similar event affecting the Series Preferred after the filing date hereof) the holders of Series D Preferred Stock, voting together as a separate class, shall be entitled to elect two
(2) members of the Board at each meeting or pursuant to each consent of the Company’s stockholders for the election of directors, and to remove from office such director and to fill any vacancy caused by the resignation, death or removal
of such director. 
 (ii) For so long as at least 3,000,000 shares of Series C-1 Preferred Stock and Series C-2
Preferred Stock remains outstanding (subject to adjustment for any stock split, reverse stock split or similar event affecting the Series Preferred after the filing date hereof) the holders of Series C-1 Preferred Stock and Series C-2 Preferred
Stock, voting together as a separate class, shall be entitled to elect one (1) member of the Board at each meeting or pursuant to each consent of the Company’s stockholders for the election of directors, and to remove from office such
director and to fill any vacancy caused by the resignation, death or removal of such director. 

 (iii) For so long as at least 1,086,957 shares of Series C-3 Preferred Stock remain
outstanding (subject to adjustment for any stock split, reverse stock split or similar event affecting the Series Preferred after the filing date hereof) the holders of Series C-3 Preferred Stock, voting as a separate class, shall be entitled to
elect one (1) member of the Board at each meeting or pursuant to each consent of the Company’s stockholders for the election of directors, and to remove from office such director and to fill any vacancy caused by the resignation, death or
removal of such director. 
 (iv) For so long as at least 2,500,000 shares of Series B Preferred Stock remain
outstanding (subject to adjustment for any stock split, reverse stock split or similar event affecting the Series Preferred after the filing date hereof) the holders of Series B Preferred Stock, voting as a separate class, shall be entitled to elect
two (2) members of the Board at each meeting or pursuant to each consent of the Company’s stockholders for the election of directors, and to remove from office such directors and to fill any vacancy caused by the resignation, death or
removal of such directors. 
 (v) The holders of Common Stock, voting as a separate class, shall be entitled to elect
one (1) member of the Board at each meeting or pursuant to each consent of the Company’s stockholders for the election of directors, and to remove from office such director and to fill any vacancy caused by the resignation, death or
removal of such director. 
 (vi) The holders of a majority of the Common Stock and Series Preferred, voting together as
a single class, shall be entitled to elect all remaining members of the Board at each meeting or pursuant to each consent of the Company’s stockholders for the election of directors, and to remove from office such directors and to fill any
vacancy caused by the resignation, death or removal of such directors. 
 (vii) No person entitled to vote at an
election for directors may cumulate votes to which such person is entitled, unless, at the time of such election, the Company is subject to Section 2115 of the California General Corporation Law (“CGCL”). During such
time or times that the Company is subject to Section 2115(b) of the CGCL, every stockholder entitled to vote at an election for directors may cumulate such stockholder’s votes and give one candidate a number of votes equal to the number of
directors to be elected multiplied by the number of votes to which such stockholder’s shares are otherwise entitled, or distribute the stockholder’s votes on the same principle among as many candidates as such stockholder desires. No
stockholder, however, shall be entitled to so cumulate such stockholder’s votes unless (i) the names of such candidate or candidates have been placed in nomination prior to the voting and (ii) the stockholder has given notice at the
meeting, prior to the voting, of such stockholder’s intention to cumulate such stockholder’s votes. If any stockholder has given proper notice to cumulate votes, all stockholders may cumulate their votes for any candidates who have been
properly placed in nomination. Under cumulative voting, the candidates receiving the highest number of votes, up to the number of directors to be elected, are elected. 

 (viii) During such time or times that the Company is subject to Section 2115(b)
of the CGCL, the Board or any individual director may be removed from office at any time without cause by the affirmative vote of the holders of at least a majority of the outstanding shares entitled to vote; provided, however, that unless
the entire Board is removed, no individual director may be removed when the votes cast against such director’s removal, or not consenting in writing to such removal, would be sufficient to elect that director if voted cumulatively at an
election which the same total number of votes were cast (or, if such action is taken by written consent, all shares entitled to vote were voted) and the entire number of directors authorized at the time of such director’s most recent election
were then being elected. 
  

	 	3.	LIQUIDATION RIGHTS. 

 (a) Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (a “Liquidation Event”), before any distribution or payment shall be
made to the holders of any Common Stock, Series A Preferred Stock, Series B Preferred Stock or Series C Preferred Stock, the holders of Series D Preferred Stock shall be entitled to be paid out of the assets of the Company legally available for
distribution, or the consideration received in such transaction, an amount per share of Series D Preferred Stock equal to two and one half (2 1/2) times the Original Issue Price plus all declared and unpaid dividends on the
Series D Preferred Stock for each share of Series D Preferred Stock held by them. If, upon any such liquidation, dissolution, or winding up, the assets of the Company (or the consideration received in such transaction) shall be insufficient to make
payment in full to all holders of Series D Preferred Stock of the liquidation preference set forth in this Section 3(a), then such assets (or consideration) shall be distributed among the holders of Series D Preferred Stock at the time
outstanding, ratably in proportion to the full amounts to which they would otherwise be respectively entitled. 
 (b)
After the payment of the full liquidation preference of the Series D Preferred Stock as set forth in Section 3(a) above, before any distribution or payment shall be made to the holders of any Common Stock, Series A Preferred Stock or Series
B Preferred Stock, the holders of Series C Preferred Stock shall be entitled to be paid out of the assets of the Company legally available for distribution, or the consideration received in such transaction, an amount per share of Series C Preferred
Stock equal to the applicable Original Issue Price plus all declared and unpaid dividends on the Series C Preferred Stock for each share of Series C Preferred Stock held by them. If, upon any such liquidation, dissolution, or winding up, the assets
of the Company (or the consideration received in such transaction) shall be insufficient to make payment in full to all holders of Series C Preferred Stock of the liquidation preference set forth in this Section 3(b), then such assets (or
consideration) shall be distributed among the holders of Series C Preferred Stock at the time outstanding, ratably in proportion to the full amounts to which they would otherwise be respectively entitled. 

(c) After the payment of the full liquidation preference of the Series D Preferred Stock and Series C Preferred Stock as set
forth in Section 3(a) and 3(b) above, before any distribution or payment shall be made to the holders of any Common Stock or Series A Preferred, the holders of Series B Preferred Stock shall be entitled to be paid out of the assets of the
Company legally available for distribution, or the consideration received in such transaction, 

 
an amount per share of Series B Preferred Stock equal to the applicable Original Issue Price plus all declared and unpaid dividends on the Series B Preferred Stock for each share of Series B
Preferred Stock held by them. If, upon any such liquidation, dissolution, or winding up, the assets of the Company (or the consideration received in such transaction) shall be insufficient to make payment in full to all holders of Series B Preferred
Stock of the liquidation preference set forth in this Section 3(c), then such assets (or consideration) shall be distributed among the holders of Series B Preferred Stock at the time outstanding, ratably in proportion to the full amounts to
which they would otherwise be respectively entitled. 
 (d) After the payment of the full liquidation preference of the
Series D Preferred Stock, Series C Preferred Stock and Series B Preferred Stock as set forth in Sections 3(a), 3(b) and 3(c) above, before any distribution or payment shall be made to the holders of any Common Stock, the holders of Series A
Preferred Stock shall be entitled to be paid out of the assets of the Company legally available for distribution, or the consideration received in such transaction, an amount per share of Series A Preferred Stock equal to the applicable Original
Issue Price plus all declared and unpaid dividends on the Series A Preferred Stock for each share of Series A Preferred Stock held by them. If, upon any such liquidation, dissolution, or winding up, the assets of the Company (or the consideration
received in such transaction) shall be insufficient to make payment in full to all holders of Series A Preferred Stock of the liquidation preference set forth in this Section 3(d), then such assets (or consideration) shall be distributed among
the holders of Series A Preferred Stock at the time outstanding, ratably in proportion to the full amounts to which they would otherwise be respectively entitled. 

(e) After the payment of the full liquidation preference of the Series Preferred as set forth in
Sections 3(a), 3(b), 3(c) and 3(d) above, the assets of the Company legally available for distribution in such Liquidation Event (or the consideration received in such transaction), if any, shall be distributed ratably to the holders of the
Common Stock, Series C Preferred Stock and Series B Preferred Stock on an as-if-converted to Common Stock basis until such holders of Series C Preferred Stock and Series B Preferred Stock have received pursuant to Sections 3(b) and 3(c) above
and this Section 3(e) an aggregate amount per share of Series B Preferred Stock and Series C Preferred Stock, respectively, equal to one and one-half
(1 1/2) times the Original Issue Price of such shares of Series B Preferred Stock or Series C Preferred Stock; thereafter, the remaining assets of the Company legally available for distribution in such
Liquidation Event (or the consideration received in such transaction), if any, shall be distributed ratably to the holders of the Common Stock. 
  

	 	4.	ASSET TRANSFER OR ACQUISITION RIGHTS. 

(a) In the event that the Company is a party to an Acquisition or Asset Transfer (as hereinafter defined), then upon the closing
of such Acquisition or Asset Transfer each holder of Series Preferred shall be entitled to receive, for each share of Series Preferred then held, out of the proceeds of such Acquisition or Asset Transfer, the greater of (i) the amount of cash,
securities or other property to which such holder would be entitled to receive in a liquidation pursuant to Section 3 hereof, or (ii) the amount of cash, securities or other property to which such holder would be entitled to receive in a
liquidation pursuant to Section 3 hereof if 

 
such holder had converted such shares of Series Preferred into Common Stock immediately prior to the closing of such Acquisition or Asset Transfer. 

(b) If an Acquisition or Asset Transfer is structured such that the aggregate consideration is payable in a series of payments
(such as earn-out payments, escrow amounts or other contingent payments), in order to give effect to the priorities and preferences described in Section 3 above and in this Section 4, (i) the portion of such consideration that is not
placed in escrow and not subject to any contingencies shall be allocated among the holders of capital stock of the Company as if such initial consideration were the only consideration payable in connection with such Acquisition or Asset Transfer,
and (ii) thereafter, any additional payments shall be allocated among the holders of capital stock of the Company, after taking into account all previous payments, as if such payment and all previous payments were received in a single payment
(the “Aggregate Payment”), and that such Aggregate Payment was the only consideration payable in connection with such Acquisition or Asset Transfer. 
 (c) For the purposes of this Section 4: (i) “Acquisition” shall mean any consolidation or merger of the Company with or into any other corporation or other entity or person, or
any other corporate reorganization, in which the stockholders of the Company (in the aggregate) immediately prior to such consolidation, merger or reorganization, own less than fifty percent (50%) of the voting power of the surviving entity
immediately after such consolidation, merger or reorganization; or (B) any transaction or series of related transactions to which the Company is a party in which in excess of fifty percent (50%) of the Company’s voting power is
transferred; provided that an Acquisition shall not include (x) any consolidation or merger effected exclusively to change the domicile of the Company, or (y) any transaction or series of transactions principally for bona fide equity
financing purposes in which cash is received by the Company or indebtedness of the Company is cancelled or converted or a combination thereof; and (ii) “Asset Transfer” shall mean a sale, lease or other disposition of all or
substantially all of the assets of the Company. 
 (d) In any Acquisition or Asset Transfer, if the consideration to be
received is securities of a corporation or other property other than cash, its value will be deemed its fair market value as determined in good faith by the Board. 
  

	 	5.	CONVERSION RIGHTS. 

 The holders of the Series Preferred shall have the following rights with respect to the conversion of the Series Preferred into shares of Common Stock (the “Conversion Rights”):

 (a) Optional Conversion. Subject to and in compliance with the provisions of this Section 5, any shares of
Series Preferred may, at the option of the holder, be converted at any time into fully-paid and nonassessable shares of Common Stock. The number of shares of Common Stock to which a holder of Series Preferred shall be entitled upon conversion shall
be the product obtained by multiplying the applicable “Series Preferred Conversion Rate” then in effect (determined as provided in Section 5(b)) by the number of shares of Series Preferred being converted. 

 (b) Series Preferred Conversion Rate. The conversion rate in effect at any time for
conversion of the Series Preferred (the “Series Preferred Conversion Rate”) shall be the quotient obtained by dividing the applicable Original Issue Price of the Series Preferred by the applicable “Series Preferred
Conversion Price,” calculated as provided in Section 5(c), provided that for purposes of Section 5(h), the Original Issue Price of the Series C-3 Preferred Stock shall be deemed to be the Original Issue Price of the Series C-2
Preferred Stock. 
 (c) Series Preferred Conversion Price. Except with respect to the Series D Preferred Stock, the
conversion price for the Series Preferred shall initially be the applicable Original Issue Price of the Series Preferred (the “Series Preferred Conversion Price”), provided that for purposes of Section 5(h), the Original
Issue Price of the Series C-3 Preferred Stock shall be deemed to be the Original Issue Price of the Series C-2 Preferred Stock. The Series Preferred Conversion Price of the Series D Preferred Stock shall be $3.15 per share as of the date of filing
this Amended and Restated Certificate of Incorporation. Such initial Series Preferred Conversion Price shall be adjusted from time to time in accordance with this Section 5. All references to the Series Preferred Conversion Price herein shall
mean the Series Preferred Conversion Price as so adjusted. 
 (d) Mechanics of Conversion. Each holder of Series
Preferred who desires to convert the same into shares of Common Stock pursuant to this Section 5 shall surrender the certificate or certificates therefor, duly endorsed, at the office of the Company or any transfer agent for the Series
Preferred, and shall give written notice to the Company at such office that such holder elects to convert the same. Such notice shall state the number of shares of Series Preferred being converted. Thereupon, the Company shall promptly issue and
deliver at such office to such holder a certificate or certificates for the number of shares of Common Stock to which such holder is entitled and shall promptly pay (i) in cash or, to the extent sufficient funds are not then legally available
therefor, in Common Stock (at the Common Stock’s fair market value determined by the Board as of the date of such conversion), any declared and unpaid dividends on the shares of Series Preferred being converted and (ii) in cash (at the
Common Stock’s fair market value determined by the Board as of the date of conversion) the value of any fractional share of Common Stock otherwise issuable to any holder of Series Preferred. Such conversion shall be deemed to have been made at
the close of business on the date of such surrender of the certificates representing the shares of Series Preferred to be converted, and the person entitled to receive the shares of Common Stock issuable upon such conversion shall be treated for all
purposes as the record holder of such shares of Common Stock on such date. 
 (e) Adjustment for Stock Splits and
Combinations. If at any time or from time to time after the date that the first share of Series D Preferred Stock is issued (the “Original Issue Date”) the Company effects a subdivision of the outstanding Common Stock
without a corresponding subdivision of the Preferred Stock, the applicable Series Preferred Conversion Price in effect immediately before that subdivision shall be proportionately decreased. Conversely, if at any time or from time to time after the
Original Issue Date the Company combines the outstanding shares of Common Stock into a smaller number of shares without a corresponding combination of the Preferred Stock, the applicable Series Preferred

 
Conversion Price in effect immediately before the combination shall be proportionately increased. Any adjustment under this Section 5(e) shall become effective at the close of business on
the date the subdivision or combination becomes effective. 
 (f) Adjustment for Reclassification, Exchange and
Substitution. If at any time or from time to time after the Original Issue Date, the Common Stock issuable upon the conversion of the Series Preferred is changed into the same or a different number of shares of any class or classes of stock,
whether by recapitalization, reclassification or otherwise (other than an Acquisition or Asset Transfer as defined in Section 4 or a subdivision or combination of shares or stock dividend or a reorganization, merger, consolidation or sale of
assets provided for elsewhere in this Section 5), in any such event each holder of Series Preferred shall then have the right to convert such stock into the kind and amount of stock and other securities and property receivable upon such
recapitalization, reclassification or other change by holders of the maximum number of shares of Common Stock into which such shares of Series Preferred could have been converted immediately prior to such recapitalization, reclassification or
change, all subject to further adjustment as provided herein or with respect to such other securities or property by the terms thereof. 
 (g) Reorganizations, Mergers or Consolidations. If at any time or from time to time after the Original Issue Date, there is a capital reorganization of the Common Stock or the merger or
consolidation of the Company with or into another corporation or another entity or person (other than an Acquisition or Asset Transfer as defined in Section 4 or a recapitalization, subdivision, combination, reclassification, exchange or
substitution of shares provided for elsewhere in this Section 5), as a part of such capital reorganization, provision shall be made so that the holders of the Series Preferred shall thereafter be entitled to receive upon conversion of the
Series Preferred the number of shares of stock or other securities or property of the Company to which a holder of the number of shares of Common Stock deliverable upon conversion would have been entitled on such capital reorganization, subject to
adjustment in respect of such stock or securities by the terms thereof. In any such case, appropriate adjustment shall be made in the application of the provisions of this Section 5 with respect to the rights of the holders of Series Preferred
after the capital reorganization to the end that the provisions of this Section 5 (including adjustment of the applicable Series Preferred Conversion Price then in effect and the number of shares issuable upon conversion of the Series
Preferred) shall be applicable after that event and be as nearly equivalent as practicable. 
 (h) Sale of Shares Below
Series Preferred Conversion Price. 
 (i) If on, or at any time or from time to time after the Original Issue Date,
the Company issues or sells, or is deemed by the express provisions of this Section 5(h) to have issued or sold, Additional Shares of Common Stock (as defined below), other than as provided in Section 5(f) or 5(g) above, for an Effective
Price (as defined below) less than the then effective Series Preferred Conversion Price of Series D Preferred Stock (and so long as the Effective Price is less than the Conversion Price of such series) (a “Qualifying Dilutive
Issuance”), then and in each such case, the then existing Series Preferred Conversion Price for the Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-3 Preferred
Stock or Series D Preferred Stock, as 

 
applicable, shall be reduced, as of the opening of business on the date of such issue or sale, to a price determined by multiplying the Series Preferred Conversion Price of the Series B-1
Preferred Stock, Series B-2 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-3 Preferred Stock or Series D Preferred Stock, as applicable, in effect immediately prior to such issuance or sale by a fraction equal to:

 (A) the numerator of which shall be (A) the number of shares of Common Stock deemed outstanding (as determined
below) immediately prior to such issue or sale, plus (B) the number of shares of Common Stock which the Aggregate Consideration (as defined below) received or deemed received by the Company for the total number of Additional Shares of Common
Stock so issued would purchase at such then-existing Series Preferred Conversion Price, and 
 (B) the denominator of
which shall be the number of shares of Common Stock deemed outstanding (as determined below) immediately prior to such issue or sale plus the total number of Additional Shares of Common Stock so issued. 

For the purposes of the preceding sentence, the number of shares of Common Stock deemed to be outstanding as of a given date shall be the
sum of (A) the number of shares of Common Stock outstanding, (B) the number of shares of Common Stock into which the then outstanding shares of Series Preferred could be converted if fully converted on the day immediately preceding the
given date, and (C) the number of shares of Common Stock which are issuable upon the exercise or conversion of all other rights, options and convertible securities outstanding on the day immediately preceding the given date. 

(ii) No adjustment shall be made to the Series Preferred Conversion Price of the Series B-1 Preferred Stock, Series B-2 Preferred
Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-3 Preferred Stock or Series D Preferred Stock, as applicable, in an amount less than one cent per share. Any adjustment otherwise required by this Section 5(h) that is not
required to be made due to the preceding sentence shall be included in any subsequent adjustment to the Series Preferred Conversion Price of the Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred
Stock, Series C-3 Preferred Stock or Series D Preferred Stock, as applicable. 
 (iii) For the purpose of making any
adjustment required under this Section 5(h), the aggregate consideration received by the Company for any issue or sale of securities (the “Aggregate Consideration”) shall be defined as: (A) to the extent it consists
of cash, be computed at the gross amount of cash received by the Company before deduction of any underwriting or similar commissions, compensation or concessions paid or allowed by the Company in connection with such issue or sale and without
deduction of any expenses payable by the Company, (B) to the extent it consists of property other than cash, be computed at the fair value of that property as determined in good faith by the Board, and (C) if Additional Shares of Common
Stock, Convertible Securities (as defined below) or rights or options to purchase either Additional Shares of Common Stock or Convertible Securities are issued or sold together with other stock or securities or other assets of the Company for a
consideration which covers both, be computed as the portion of the consideration so received that may be reasonably determined 

 
in good faith by the Board to be allocable to such Additional Shares of Common Stock, Convertible Securities or rights or options. 

(iv) For the purpose of the adjustment required under this Section 5(h), if the Company issues or sells (x) Preferred
Stock or other stock, options, warrants, purchase rights or other securities convertible into, Additional Shares of Common Stock (such convertible stock or securities being herein referred to as “Convertible Securities”) or
(y) rights or options for the purchase of Additional Shares of Common Stock or Convertible Securities and if the Effective Price of such Additional Shares of Common Stock is less than the Series Preferred Conversion Price, in each case the
Company shall be deemed to have issued at the time of the issuance of such rights or options or Convertible Securities the maximum number of Additional Shares of Common Stock issuable upon exercise or conversion thereof and to have received as
consideration for the issuance of such shares an amount equal to the total amount of the consideration, if any, received by the Company for the issuance of such rights or options or Convertible Securities plus: 

(A) in the case of such rights or options, the minimum amounts of consideration, if any, payable to the Company upon the exercise
of such rights or options; and 
 (B) in the case of Convertible Securities, the minimum amounts of consideration, if
any, payable to the Company upon the conversion thereof (other than by cancellation of liabilities or obligations evidenced by such Convertible Securities); provided that if the minimum amounts of such consideration cannot be ascertained, but
are a function of antidilution or similar protective clauses, the Company shall be deemed to have received the minimum amounts of consideration without reference to such clauses. 

(C) If the minimum amount of consideration payable to the Company upon the exercise or conversion of rights, options or
Convertible Securities is reduced over time or on the occurrence or non-occurrence of specified events other than by reason of antidilution adjustments, the Effective Price shall be recalculated using the figure to which such minimum amount of
consideration is reduced; provided further, that if the minimum amount of consideration payable to the Company upon the exercise or conversion of such rights, options or Convertible Securities is subsequently increased, the Effective Price
shall be again recalculated using the increased minimum amount of consideration payable to the Company upon the exercise or conversion of such rights, options or Convertible Securities. 

(D) No further adjustment of the Series Preferred Conversion Price of the Series B-1 Preferred Stock, Series B-2 Preferred Stock,
Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-3 Preferred Stock or Series D Preferred Stock, as applicable, as adjusted upon the issuance of such rights, options or Convertible Securities, shall be made as a result of the actual
issuance of Additional Shares of Common Stock or the exercise of any such rights or options or the conversion of any such Convertible Securities. If any such rights or options or the conversion privilege represented by any such Convertible
Securities shall expire without having been exercised, the Series Preferred Conversion Price as adjusted upon the issuance of such rights, options or Convertible Securities 

 
shall be readjusted to the Series Preferred Conversion Price which would have been in effect had an adjustment been made on the basis that the only Additional Shares of Common Stock so issued
were the Additional Shares of Common Stock, if any, actually issued or sold on the exercise of such rights or options or rights of conversion of such Convertible Securities, and such Additional Shares of Common Stock, if any, were issued or sold for
the consideration actually received by the Company upon such exercise, plus the consideration, if any, actually received by the Company for the granting of all such rights or options, whether or not exercised, plus the consideration received for
issuing or selling the Convertible Securities actually converted, plus the consideration, if any, actually received by the Company (other than by cancellation of liabilities or obligations evidenced by such Convertible Securities) on the conversion
of such Convertible Securities, provided that such readjustment shall not apply to prior conversions of Series B Preferred Stock and Series C Preferred Stock. 
 (v) For the purpose of making any adjustment to the Conversion Price of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock required under this Section 5(h),
“Additional Shares of Common Stock” shall mean all shares of Common Stock issued by the Company or deemed to be issued pursuant to this Section 5(h) (including shares of Common Stock subsequently reacquired or retired by the Company),
other than: 
 (A) shares of Common Stock issued upon conversion of the Series Preferred; 

(B) shares of Common Stock or Convertible Securities issued after the Original Issue Date to employees, officers or directors of,
or consultants or advisors to the Company or any subsidiary pursuant to stock purchase or stock option plans or other arrangements that are approved by the Board; 
 (C) shares of Common Stock issued pursuant to the exercise of Convertible Securities outstanding as of the Original Issue Date; 

(D) shares of Common Stock or Convertible Securities issued for consideration other than cash pursuant to a merger,
consolidation, acquisition, strategic alliance or similar business combination approved by the Board; 
 (E) shares of
Common Stock or Convertible Securities issued pursuant to any equipment loan or leasing arrangement, real property leasing arrangement or debt financing from a bank or similar financial institution approved by the Board; 

(F) shares of Common Stock or Convertible Securities issued to third-party service providers in exchange for or as partial
consideration for services rendered to the Company; 
 (G) any Common Stock or Convertible Securities issued in
connection with strategic transactions involving the Company and other entities, including (i) joint ventures, manufacturing, licensing, marketing or distribution arrangements or 

 
(ii) technology transfer or development arrangements; provided that the issuance of shares therein has been approved by the Board; and 

(H) shares of Series D Preferred Stock. 
 References to Common Stock in the subsections of this clause (v) above shall mean all shares of Common Stock issued by the Company or deemed to be issued pursuant to this Section 5(h). The
“Effective Price” of Additional Shares of Common Stock shall mean the quotient determined by dividing the total number of Additional Shares of Common Stock issued or sold, or deemed to have been issued or sold by the Company under this
Section 5(h), into the Aggregate Consideration received, or deemed to have been received by the Company for such issue under this Section 5(h), for such Additional Shares of Common Stock. In the event that the number of shares of
Additional Shares of Common Stock or the Effective Price cannot be ascertained at the time of issuance, such Additional Shares of Common Stock shall be deemed issued immediately upon the occurrence of the first event that makes such number of shares
or the Effective Price, as applicable, determinable. 
 (i) In the event that the Company issues or sells, or is deemed
to have issued or sold, Additional Shares of Common Stock in a Qualifying Dilutive Issuance (the “First Dilutive Issuance”), then in the event that the Company issues or sells, or is deemed to have issued or sold, Additional
Shares of Common Stock in a Qualifying Dilutive Issuance other than the First Dilutive Issuance as a part of the same transaction or series of related transactions as the First Dilutive Issuance (a “Subsequent Dilutive
Issuance”), then and in each such case upon a Subsequent Dilutive Issuance the Series Preferred Conversion Price shall be reduced to the Series Preferred Conversion Price that would have been in effect had the First Dilutive Issuance
and each Subsequent Dilutive Issuance all occurred on the closing date of the First Dilutive Issuance. 
 (j) Certificate of
Adjustment. In each case of an adjustment or readjustment of the Series Preferred Conversion Price for the number of shares of Common Stock or other securities issuable upon conversion of the Series Preferred, if the Series Preferred is then
convertible pursuant to this Section 5, the Company, at its expense, shall compute such adjustment or readjustment in accordance with the provisions hereof and prepare a certificate showing such adjustment or readjustment, and shall mail such
certificate, by first class mail, postage prepaid, to each registered holder of Series Preferred at the holder’s address as shown in the Company’s books. The certificate shall set forth such adjustment or readjustment,
showing in detail the facts upon which such adjustment or readjustment is based. 
 (k) Notices of Record Date. Upon
(i) any taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend or other distribution, or (ii) any Acquisition (as defined in
Section 4) or other capital reorganization of the Company, any reclassification or recapitalization of the capital stock of the Company, any merger or consolidation of the Company with or into any other corporation, or any Asset Transfer (as
defined in Section 4), or any voluntary or involuntary dissolution, liquidation or winding up of the Company, the Company shall mail to each holder of Series Preferred at least ten (10) days prior to the record

 
date specified therein (or such shorter period approved by the holders of a majority of the outstanding Series Preferred) a notice specifying (A) the date on which any such record is to be
taken for the purpose of such dividend or distribution and a description of such dividend or distribution, (B) the date on which any such Acquisition, reorganization, reclassification, transfer, consolidation, merger, Asset Transfer,
dissolution, liquidation or winding up is expected to become effective, and (C) the date, if any, that is to be fixed as to when the holders of record of Common Stock (or other securities) shall be entitled to exchange their shares of Common
Stock (or other securities) for securities or other property deliverable upon such Acquisition, reorganization, reclassification, transfer, consolidation, merger, Asset Transfer, dissolution, liquidation or winding up. 

(l) Automatic Conversion. 
 (i) Each share of Series Preferred shall automatically be converted into shares of Common Stock, based on the then-effective Series Preferred Conversion Price, (A) at any time upon the
affirmative election of the holders of at least a majority of the outstanding shares of the Series Preferred, provided, however, so long as Medicis Pharmaceutical Corporation, a Delaware corporation, together with any of its subsidiaries
(“Medicis”) holds at least 1,086,957 shares of Series C-3 Preferred Stock (as adjusted for stock splits, dividends, recapitalizations and the like after the filing date
hereof), Medicis’ affirmative election shall be required to effect any automatic conversion of the Series C-3 Preferred Stock pursuant to this subsection 5(m)(i)(A), (B) immediately upon the closing of a firmly underwritten public offering
pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of Common Stock for the account of the Company (a “Public
Offering”), upon the affirmative election of the holders of at least a majority of the outstanding shares of the Series Preferred, or (C) immediately upon the closing of a Public Offering in which the
per share price is at least $13.35 (as adjusted for stock splits, dividends, recapitalizations and the like after the filing date hereof), and the gross cash proceeds to the Company (before underwriting discounts, commissions and fees) are at least
$50,000,000 (in each case, a “Qualified Public Offering”). 
 (ii) In addition, (A) each outstanding share of Series A Preferred Stock shall automatically be converted into shares of Common Stock, based on the then-effective Series Preferred Conversion
Price of the Series A Preferred Stock, at any time upon the affirmative election of the holders of at least a majority of the outstanding shares of the Series A Preferred Stock, (B) each outstanding share of Series B Preferred Stock shall
automatically be converted into shares of Common Stock, based on the then-effective Series Preferred Conversion Price of the Series B Preferred Stock, at any time upon the affirmative election of the holders of at least a majority of the outstanding
shares of the Series B Preferred Stock, (C) each outstanding share of Series C-1 Preferred Stock and Series C-2 Preferred Stock shall automatically be converted into shares of Common Stock, based on the then-effective applicable Series
Preferred Conversion Price of the Series C-1 Preferred Stock and the Series C-2 Preferred Stock, respectively, at any time upon the affirmative election of the holders of at least a majority of the outstanding shares of the Series C-1 Preferred
Stock and Series C-2 Preferred Stock voting together as a single class, (D) each outstanding share of Series C-3 Preferred Stock shall automatically be converted into shares of Common Stock, based on the

 
then-effective Series Preferred Conversion Price of the Series C-3 Preferred Stock, at any time upon the affirmative election of the holders of at least a majority of the outstanding shares of
the Series C-3 Preferred Stock, provided, however, so long as Medicis, together with any of its subsidiaries, holds at least 1,086,957 shares of Series C-3 Preferred Stock (as adjusted for stock splits, dividends, recapitalizations and the
like after the filing date hereof), Medicis’ affirmative election shall be required to effect any automatic conversion of the Series C-3 Preferred Stock pursuant to this subsection 5(m)(ii)(D) that occurs during the thirty (30) day period
following the Company’s completion of Phase 2 meeting with the United States Food and Drug Administration, (E) with respect to the Series C Preferred Stock, each outstanding share of the Series C Preferred Stock shall automatically be
converted into shares of Common Stock, based on the then-effective applicable Series Preferred Conversion Prices of the Series C-1 Preferred Stock, the Series C-2 Preferred Stock and the Series C-3 Preferred Stock, respectively, at any time upon the
affirmative election of Medicis and the holders of at least 67% of the outstanding shares of the Series C Preferred Stock voting together as a single class, and (F) each outstanding share of Series D Preferred Stock shall automatically be
converted into shares of Common Stock, based on the then-effective Series Preferred Conversion Price of the Series D Preferred Stock, at any time upon the affirmative election of the holders of at least a majority of the outstanding shares of the
Series D Preferred Stock. 
 (iii) Upon the occurrence of any conversion of any class or series of Series Preferred
specified in Section 5(m)(i) or 5(m)(ii) above, the outstanding shares of Series Preferred shall be converted automatically without any further action by the holders of such shares and whether or not the certificates representing such shares
are surrendered to the Company or its transfer agent; provided, however, that the Company shall not be obligated to issue certificates evidencing the shares of Common Stock issuable upon such conversion unless the certificates evidencing such
shares of Series Preferred are either delivered to the Company or its transfer agent as provided below, or the holder notifies the Company or its transfer agent that such certificates have been lost, stolen or destroyed and executes an agreement
satisfactory to the Company to indemnify the Company from any loss incurred by it in connection with such certificates. Upon the occurrence of such automatic conversion of the Series Preferred, the holders of Series Preferred shall surrender the
certificates representing such shares at the office of the Company or any transfer agent for the Series Preferred. Thereupon, there shall be issued and delivered to such holder promptly at such office and in its name as shown on such surrendered
certificate or certificates, a certificate or certificates for the number of shares of Common Stock into which the shares of Series Preferred surrendered were convertible on the date on which such automatic conversion occurred, and any declared and
unpaid dividends shall be paid in accordance with the provisions of Section 5(d). 
 (m) Fractional Shares. No
fractional shares of Common Stock shall be issued upon conversion of Series Preferred. All shares of Common Stock (including fractions thereof) issuable upon conversion of more than one share of Series Preferred by a holder thereof shall be
aggregated for purposes of determining whether the conversion would result in the issuance of any fractional share. If, after the aforementioned aggregation, the conversion would result in the issuance of any fractional share, the Company shall, in
lieu of issuing any fractional share, pay cash equal to the product of such fraction multiplied by the Common Stock’s fair market value (as determined by the Board) on the date of conversion. 

 (n) Reservation of Stock Issuable Upon Conversion. The Company shall at all times
reserve and keep available out of its authorized but unissued shares of Common Stock, solely for the purpose of effecting the conversion of the shares of the Series Preferred, such number of its shares of Common Stock as shall from time to time be
sufficient to effect the conversion of all outstanding shares of the Series Preferred. If at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the
Series Preferred, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purpose.

 (o) Notices. Any notice required by the provisions of this Section 5 shall be in writing and shall be deemed
effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail (with a copy to be sent to counsel for the party to be notified to the extent requested in writing by such party) or
facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one
(1) day after deposit with a nationally recognized overnight courier, costs prepaid and specifying next day delivery, with verification of receipt. All notices shall be addressed to each holder of record at the address of such holder appearing
on the books of the Company. 
 (p) Payment of Taxes. The Company will pay all taxes (other than taxes based upon
income) and other governmental charges that may be imposed with respect to the issue or delivery of shares of Common Stock upon conversion of shares of Series Preferred, excluding any tax or other charge imposed in connection with any transfer
involved in the issue and delivery of shares of Common Stock in a name other than that in which the shares of Series Preferred so converted were registered. 
  

	 	6.	NO REISSUANCE OF SERIES PREFERRED. 

No shares of Series Preferred acquired by the Company by reason of redemption, purchase, conversion or otherwise shall be reissued.

 V. 
 A. The liability of the directors of the Company for monetary damages shall be eliminated to the fullest extent under applicable law. 

B. The Company is authorized to provide indemnification of agents (as defined in Section 317 of the CGCL) for breach of duty
to the Company and its stockholders through bylaw provisions or through agreements with the agents, or through stockholder resolutions, or otherwise, in excess of the indemnification otherwise permitted by Section 317 of the CGCL, subject, at
any time or times that the Company is subject to Section 2115(b) of the CGCL, to the limits on such excess indemnification set forth in Section 204 of the CGCL. 

 C. Any repeal or modification of this Article V shall only be prospective and shall
not affect the rights under this Article V in effect at the time of the alleged occurrence of any action or omission to act giving rise to liability. 
 VI. 
 For the management of the business and for the conduct of the affairs
of the Company, and in further definition, limitation and regulation of the powers of the Company, of its directors and of its stockholders or any class thereof, as the case may be, it is further provided that: 

A. The management of the business and the conduct of the affairs of the Company shall be vested in its Board. The number of
directors which shall constitute the whole Board shall be fixed by the Board in the manner provided in the Bylaws, subject to any restrictions which may be set forth in this Restated Certificate. 

B. The Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the Company. The stockholders shall also
have the power to adopt, amend or repeal the Bylaws of the Company; provided however, that, in addition to any vote of the holders of any class or series of stock of the Company required by law or by this Certificate of Incorporation, the
affirmative vote of the holders of at least a majority of the voting power of all of the then-outstanding shares of the capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class, shall be
required to adopt, amend or repeal any provision of the Bylaws of the Company. 
 C. The directors of the Company need
not be elected by written ballot unless the Bylaws so provide. 
 * * * * 

FOUR: This Amended and Restated Certificate of Incorporation has been duly approved by the Board of the Company. 

FIVE: This Amended and Restated Certificate of Incorporation was approved by the holders of the requisite number of shares of said
Corporation in accordance with Section 228 of the DGCL. This Amended and Restated Certificate of Incorporation has been duly adopted in accordance with the provisions of Sections 242 and 245 of the DGCL by the stockholders of the Company.

 IN WITNESS
WHEREOF, REVANCE THERAPEUTICS, INC. has caused this Amended and Restated Certificate of Incorporation to be signed by its President this 10th day of May, 2010. 

 

	
	REVANCE THERAPEUTICS, INC.
	
	 /s/ L. Daniel Browne

	L. Daniel Browne
	President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]